

(12) **United States Patent**  
**Hayter**

(10) **Patent No.:** **US 9,801,571 B2**  
(45) **Date of Patent:** **Oct. 31, 2017**

(54) **METHOD AND APPARATUS FOR PROVIDING DATA PROCESSING AND CONTROL IN MEDICAL COMMUNICATION SYSTEM**

(71) Applicant: **Abbott Diabetes Care Inc.**, Alameda, CA (US)

(72) Inventor: **Gary Alan Hayter**, Oakland, CA (US)

(73) Assignee: **Abbott Diabetes Care Inc.**, Alameda, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1022 days.

(21) Appl. No.: **14/028,358**

(22) Filed: **Sep. 16, 2013**

(65) **Prior Publication Data**

US 2014/0018642 A1 Jan. 16, 2014

**Related U.S. Application Data**

(63) Continuation of application No. 13/356,598, filed on Jan. 23, 2012, now Pat. No. 8,571,808, which is a continuation of application No. 12/152,623, filed on May 14, 2008, now Pat. No. 8,103,471.

(60) Provisional application No. 60/917,859, filed on May 14, 2007.

(51) **Int. Cl.**

**A61B 5/145** (2006.01)

**A61B 5/1473** (2006.01)

**A61B 5/1495** (2006.01)

**A61B 5/00** (2006.01)

**G06F 19/00** (2011.01)

(52) **U.S. Cl.**

CPC ..... **A61B 5/14532** (2013.01); **A61B 5/002** (2013.01); **A61B 5/1473** (2013.01); **A61B 5/1495** (2013.01); **G06F 19/3456** (2013.01);

**A61B 2560/0223** (2013.01); **A61B 2560/0252** (2013.01); **G06F 19/3412** (2013.01); **G06F 19/3437** (2013.01); **G06F 19/3487** (2013.01)

(58) **Field of Classification Search**

CPC ..... **G06F 19/3437**; **G06F 19/3456**; **G06F 19/3487**; **A61B 5/145**

USPC ..... **702/19**; **600/345**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

3,581,062 A	5/1971	Aston
3,926,760 A	12/1975	Allen et al.
3,949,388 A	4/1976	Fuller
3,960,497 A	6/1976	Acord et al.
4,033,330 A	7/1977	Willis et al.
4,036,749 A	7/1977	Anderson
4,055,175 A	10/1977	Clemens et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

CA	2143172	7/2005
CA	2396613	3/2008

(Continued)

**OTHER PUBLICATIONS**

Hovorka, R., et al., "Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes", *Physiological Measurement*, vol. 55, Jul. 2004, pp. 905-920.

(Continued)


*Primary Examiner* — Mohamed Charioui

(74) *Attorney, Agent, or Firm* — Jackson & Co., LLP

(57) **ABSTRACT**

Methods and apparatus for providing data processing and control for use in a medical communication system are provided.

**15 Claims, 20 Drawing Sheets**



(56)

## References Cited

## U.S. PATENT DOCUMENTS

4,129,128 A	12/1978	McFarlane	5,425,868 A	6/1995	Pedersen
4,245,634 A	1/1981	Albisser et al.	5,429,602 A	7/1995	Hauser
4,327,725 A	5/1982	Cortese et al.	5,431,160 A	7/1995	Wilkins
4,344,438 A	8/1982	Schultz	5,431,921 A	7/1995	Thombre
4,349,728 A	9/1982	Phillips et al.	5,438,983 A	8/1995	Falcone
4,373,527 A	2/1983	Fischell	5,462,645 A	10/1995	Albery et al.
4,392,849 A	7/1983	Petre et al.	5,472,317 A	12/1995	Field et al.
4,425,920 A	1/1984	Bourland et al.	5,489,414 A	2/1996	Schreiber et al.
4,431,004 A	2/1984	Bessman et al.	5,497,772 A	3/1996	Schulman et al.
4,441,968 A	4/1984	Emmer et al.	5,505,828 A	4/1996	Wong et al.
4,464,170 A	8/1984	Clemens et al.	5,507,288 A	4/1996	Bocker et al.
4,478,976 A	10/1984	Goertz et al.	5,509,410 A	4/1996	Hill et al.
4,494,950 A	1/1985	Fischell	5,514,718 A	5/1996	Lewis et al.
4,509,531 A	4/1985	Ward	5,531,878 A	7/1996	Vadgama et al.
4,527,240 A	7/1985	Kvitash	5,532,686 A	7/1996	Urbas et al.
4,538,616 A	9/1985	Rogoff	5,552,997 A	9/1996	Massart
4,619,793 A	10/1986	Lee	5,555,190 A	9/1996	Derby et al.
4,671,288 A	6/1987	Gough	5,564,434 A	10/1996	Halperin et al.
4,703,756 A	11/1987	Gough et al.	5,568,400 A	10/1996	Stark et al.
4,731,726 A	3/1988	Allen, III	5,568,806 A	10/1996	Cheney, II et al.
4,749,985 A	6/1988	Corsberg	5,569,186 A	10/1996	Lord et al.
4,757,022 A	7/1988	Shults et al.	5,582,184 A	12/1996	Erickson et al.
4,777,953 A	10/1988	Ash et al.	5,586,553 A	12/1996	Halili et al.
4,779,618 A	10/1988	Mund et al.	5,593,852 A	1/1997	Heller et al.
4,847,785 A	7/1989	Stephens	5,601,435 A	2/1997	Quy
4,854,322 A	8/1989	Ash et al.	5,609,575 A	3/1997	Larson et al.
4,871,351 A	10/1989	Feingold	5,628,310 A	5/1997	Rao et al.
4,890,620 A	1/1990	Gough	5,634,468 A	6/1997	Platt et al.
4,925,268 A	5/1990	Iyer et al.	5,653,239 A	8/1997	Pompei et al.
4,953,552 A	9/1990	DeMarzo	5,660,163 A	8/1997	Schulman et al.
4,986,271 A	1/1991	Wilkins	5,665,222 A	9/1997	Heller et al.
4,995,402 A	2/1991	Smith et al.	5,707,502 A	1/1998	McCaffrey et al.
5,000,180 A	3/1991	Kuypers et al.	5,711,001 A	1/1998	Bussan et al.
5,002,054 A	3/1991	Ash et al.	5,711,861 A	1/1998	Ward et al.
5,019,974 A	5/1991	Beckers	5,724,030 A	3/1998	Urbas et al.
5,050,612 A	9/1991	Matsumura	5,726,646 A	3/1998	Bane et al.
5,051,688 A	9/1991	Murase et al.	5,733,259 A	3/1998	Valcke et al.
5,055,171 A	10/1991	Peck	5,735,285 A	4/1998	Albert et al.
5,068,536 A	11/1991	Rosenthal	5,748,103 A	5/1998	Flach et al.
5,082,550 A	1/1992	Rishpon et al.	5,749,907 A	5/1998	Mann
5,106,365 A	4/1992	Hernandez	5,772,586 A	6/1998	Heinonen et al.
5,122,925 A	6/1992	Inpyin	5,791,344 A	8/1998	Schulman et al.
5,135,004 A	8/1992	Adams et al.	5,804,047 A	9/1998	Karube et al.
5,165,407 A	11/1992	Wilson et al.	5,833,603 A	11/1998	Kovacs et al.
5,202,261 A	4/1993	Musho et al.	5,842,189 A	11/1998	Keeler et al.
5,204,264 A	4/1993	Kaminer et al.	5,891,049 A	4/1999	Cyrus et al.
5,210,778 A	5/1993	Massart	5,899,855 A	5/1999	Brown
5,228,449 A	7/1993	Christ et al.	5,914,026 A	6/1999	Blubaugh, Jr. et al.
5,231,988 A	8/1993	Wernicke et al.	5,919,141 A	7/1999	Money et al.
5,243,696 A	9/1993	Carr et al.	5,925,021 A	7/1999	Castellano et al.
5,246,867 A	9/1993	Lakowicz et al.	5,935,224 A	8/1999	Svancarek et al.
5,251,126 A	10/1993	Kahn et al.	5,942,979 A	8/1999	Luppino
5,262,035 A	11/1993	Gregg et al.	5,951,485 A	9/1999	Cyrus et al.
5,262,305 A	11/1993	Heller et al.	5,957,854 A	9/1999	Besson et al.
5,264,104 A	11/1993	Gregg et al.	5,961,451 A	10/1999	Reber et al.
5,264,105 A	11/1993	Gregg et al.	5,964,993 A	10/1999	Blubaugh, Jr. et al.
5,279,294 A	1/1994	Anderson et al.	5,965,380 A	10/1999	Heller et al.
5,285,792 A	2/1994	Sjoquist et al.	5,971,922 A	10/1999	Arita et al.
5,293,877 A	3/1994	O'Hara et al.	5,980,708 A	11/1999	Champagne et al.
5,299,571 A	4/1994	Mastrototaro	5,995,860 A	11/1999	Sun et al.
5,320,725 A	6/1994	Gregg et al.	6,001,067 A	12/1999	Shults et al.
5,322,063 A	6/1994	Allen et al.	6,024,699 A	2/2000	Surwit et al.
5,330,634 A	7/1994	Wong et al.	6,028,413 A	2/2000	Brockmann
5,340,722 A	8/1994	Wolfbeis et al.	6,049,727 A	4/2000	Crothall
5,342,789 A	8/1994	Chick et al.	6,052,565 A	4/2000	Ishikura et al.
5,356,786 A	10/1994	Heller et al.	6,066,243 A	5/2000	Anderson et al.
5,360,404 A	11/1994	Novacek et al.	6,083,710 A	7/2000	Heller et al.
5,372,427 A	12/1994	Padovani et al.	6,088,608 A	7/2000	Schulman et al.
5,379,238 A	1/1995	Stark	6,091,976 A	7/2000	Pfeiffer et al.
5,384,547 A	1/1995	Lynk et al.	6,091,987 A	7/2000	Thompson
5,390,671 A	2/1995	Lord et al.	6,093,172 A	7/2000	Funderburk et al.
5,391,250 A	2/1995	Cheney, II et al.	6,096,364 A	8/2000	Bok et al.
5,408,999 A	4/1995	Singh et al.	6,103,033 A	8/2000	Say et al.
5,410,326 A	4/1995	Goldstein	6,117,290 A	9/2000	Say et al.
5,411,647 A	5/1995	Johnson et al.	6,119,028 A	9/2000	Schulman et al.
			6,120,676 A	9/2000	Heller et al.
			6,121,009 A	9/2000	Heller et al.
			6,121,611 A	9/2000	Lindsay et al.
			6,122,351 A	9/2000	Schlueter, Jr. et al.



(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,130,623 A	10/2000	MacLellan et al.	6,585,644 B2	7/2003	Lebel et al.
6,134,461 A	10/2000	Say et al.	6,591,125 B1	7/2003	Buse et al.
6,143,164 A	11/2000	Heller et al.	6,595,919 B2	7/2003	Berner et al.
6,144,871 A	11/2000	Saito et al.	6,605,200 B1	8/2003	Mao et al.
6,157,850 A	12/2000	Diab et al.	6,605,201 B1	8/2003	Mao et al.
6,159,147 A	12/2000	Lichter et al.	6,607,509 B2	8/2003	Bobroff et al.
6,162,611 A	12/2000	Heller et al.	6,610,012 B2	8/2003	Mault
6,175,752 B1	1/2001	Say et al.	6,631,281 B1	10/2003	Kastle
6,200,265 B1	3/2001	Walsh et al.	6,633,772 B2	10/2003	Ford et al.
6,212,416 B1	4/2001	Ward et al.	6,635,014 B2	10/2003	Starkweather et al.
6,219,574 B1	4/2001	Cormier et al.	6,635,167 B1	10/2003	Batman et al.
6,223,283 B1	4/2001	Chaiken et al.	6,641,533 B2	11/2003	Causey, III et al.
6,233,471 B1	5/2001	Berner et al.	6,648,821 B2	11/2003	Lebel et al.
6,248,067 B1	6/2001	Causey, III et al.	6,654,625 B1	11/2003	Say et al.
6,254,586 B1	7/2001	Mann et al.	6,656,114 B1	12/2003	Poulsen et al.
6,270,455 B1	8/2001	Brown	6,658,396 B1	12/2003	Tang et al.
6,275,717 B1	8/2001	Gross et al.	6,659,948 B2	12/2003	Lebel et al.
6,283,761 B1	9/2001	Joao	6,668,196 B1	12/2003	Villegas et al.
6,284,478 B1	9/2001	Heller et al.	6,675,030 B2	1/2004	Ciuczak et al.
6,291,200 B1	9/2001	LeJeune et al.	6,676,816 B2	1/2004	Mao et al.
6,293,925 B1	9/2001	Safabash et al.	6,687,546 B2	2/2004	Lebel et al.
6,294,997 B1	9/2001	Paratore et al.	6,689,056 B1	2/2004	Kilcoyne et al.
6,295,506 B1	9/2001	Heinonen et al.	6,694,191 B2	2/2004	Starkweather et al.
6,299,347 B1	10/2001	Pompei	6,695,860 B1	2/2004	Ward et al.
6,306,104 B1	10/2001	Cunningham et al.	6,698,269 B2	3/2004	Baber et al.
6,309,884 B1	10/2001	Cooper et al.	6,702,857 B2	3/2004	Brauker et al.
6,314,317 B1	11/2001	Willis	6,730,025 B1	5/2004	Platt
6,329,161 B1	12/2001	Heller et al.	6,731,976 B2	5/2004	Penn et al.
6,348,640 B1	2/2002	Navot et al.	6,733,446 B2	5/2004	Lebel et al.
6,359,270 B1	3/2002	Bridson	6,735,183 B2	5/2004	O'Toole et al.
6,359,444 B1	3/2002	Grimes	6,740,075 B2	5/2004	Lebel et al.
6,360,888 B1	3/2002	McIvor et al.	6,740,518 B1	5/2004	Duong et al.
6,366,794 B1	4/2002	Moussy et al.	6,741,877 B1	5/2004	Shults et al.
6,377,828 B1	4/2002	Chaiken et al.	6,746,582 B2	6/2004	Heller et al.
6,379,301 B1	4/2002	Worthington et al.	6,758,810 B2	7/2004	Lebel et al.
6,387,048 B1	5/2002	Schulman et al.	6,770,030 B1	8/2004	Schaupp et al.
6,400,974 B1	6/2002	Lesho	6,789,195 B1	9/2004	Prihoda et al.
6,405,066 B1	6/2002	Essenpreis et al.	6,790,178 B1	9/2004	Mault et al.
6,413,393 B1	7/2002	Van Antwerp et al.	6,804,558 B2	10/2004	Haller et al.
6,416,471 B1	7/2002	Kumar et al.	6,809,653 B1	10/2004	Mann et al.
6,418,346 B1	7/2002	Nelson et al.	6,810,290 B2	10/2004	Lebel et al.
6,424,847 B1	7/2002	Mastrototaro et al.	6,811,533 B2	11/2004	Lebel et al.
6,427,088 B1	7/2002	Bowman, IV et al.	6,811,534 B2	11/2004	Bowman, IV et al.
6,440,068 B1	8/2002	Brown et al.	6,813,519 B2	11/2004	Lebel et al.
6,471,689 B1	10/2002	Joseph et al.	6,850,790 B2	2/2005	Berner et al.
6,478,736 B1	11/2002	Mault	6,862,465 B2	3/2005	Shults et al.
6,484,046 B1	11/2002	Say et al.	6,865,407 B2	3/2005	Kimball et al.
6,493,069 B1	12/2002	Nagashimada et al.	6,873,268 B2	3/2005	Lebel et al.
6,496,729 B2	12/2002	Thompson	6,878,112 B2	4/2005	Linberg et al.
6,497,655 B1	12/2002	Linberg et al.	6,881,551 B2	4/2005	Heller et al.
6,498,043 B1	12/2002	Schulman et al.	6,882,940 B2	4/2005	Potts et al.
6,514,718 B2	2/2003	Heller et al.	6,892,085 B2	5/2005	McIvor et al.
6,520,326 B2	2/2003	McIvor et al.	6,895,263 B2	5/2005	Shin et al.
6,544,212 B2	4/2003	Galley et al.	6,895,265 B2	5/2005	Silver
6,546,268 B1	4/2003	Ishikawa et al.	6,923,763 B1	8/2005	Kovatchev et al.
6,549,796 B2	4/2003	Sohrab	6,923,764 B2	8/2005	Aceti et al.
6,551,494 B1	4/2003	Heller et al.	6,931,327 B2	8/2005	Goode, Jr. et al.
6,554,798 B1	4/2003	Mann et al.	6,932,894 B2	8/2005	Mao et al.
6,558,320 B1	5/2003	Causey, III et al.	6,936,006 B2	8/2005	Sabra
6,558,321 B1	5/2003	Burd et al.	6,940,403 B2	9/2005	Kail, IV
6,558,351 B1	5/2003	Steil et al.	6,941,163 B2	9/2005	Ford et al.
6,560,471 B1	5/2003	Heller et al.	6,942,518 B2	9/2005	Liamos et al.
6,561,975 B1	5/2003	Pool et al.	6,950,708 B2	9/2005	Bowman, IV et al.
6,561,978 B1	5/2003	Conn et al.	6,958,705 B2	10/2005	Lebel et al.
6,562,001 B2	5/2003	Lebel et al.	6,968,294 B2	11/2005	Gutta et al.
6,564,105 B2	5/2003	Starkweather et al.	6,971,274 B2	12/2005	Olin
6,565,509 B1	5/2003	Say et al.	6,974,437 B2	12/2005	Lebel et al.
6,571,128 B2	5/2003	Lebel et al.	6,983,176 B2	1/2006	Gardner et al.
6,572,545 B2	6/2003	Knobbe et al.	6,990,366 B2	1/2006	Say et al.
6,574,490 B2	6/2003	Abbink et al.	6,997,907 B2	2/2006	Safabash et al.
6,574,510 B2	6/2003	Von Arx et al.	6,998,247 B2	2/2006	Monfre et al.
6,576,101 B1	6/2003	Heller et al.	6,999,854 B2	2/2006	Roth
6,577,899 B2	6/2003	Lebel et al.	7,003,336 B2	2/2006	Holker et al.
6,579,231 B1	6/2003	Phipps	7,003,340 B2	2/2006	Say et al.
6,579,690 B1	6/2003	Bonnecaze et al.	7,003,341 B2	2/2006	Say et al.
			7,009,511 B2	3/2006	Mazar et al.
			7,015,817 B2	3/2006	Copley et al.
			7,016,713 B2	3/2006	Gardner et al.
			7,020,508 B2	3/2006	Stivoric et al.



(56)

## References Cited

## U.S. PATENT DOCUMENTS

7,022,072 B2	4/2006	Fox et al.	7,497,827 B2	3/2009	Brister et al.
7,022,219 B2	4/2006	Mansouri et al.	7,519,408 B2	4/2009	Rasdal et al.
7,024,236 B2	4/2006	Ford et al.	7,547,281 B2	6/2009	Hayes et al.
7,024,245 B2	4/2006	Lebel et al.	7,565,197 B2	7/2009	Haubrich et al.
7,025,425 B2	4/2006	Kovatchev et al.	7,569,030 B2	8/2009	Lebel et al.
7,027,848 B2	4/2006	Robinson et al.	7,574,266 B2	8/2009	Dudding et al.
7,027,931 B1	4/2006	Jones et al.	7,583,990 B2	9/2009	Goode, Jr. et al.
7,029,444 B2	4/2006	Shin et al.	7,591,801 B2	9/2009	Brauker et al.
7,041,068 B2	5/2006	Freeman et al.	7,599,726 B2	10/2009	Goode, Jr. et al.
7,041,468 B2	5/2006	Drucker et al.	7,602,310 B2	10/2009	Mann et al.
7,043,305 B2	5/2006	KenKnight et al.	7,604,178 B2	10/2009	Stewart
7,046,153 B2	5/2006	Oja et al.	7,613,491 B2	11/2009	Boock et al.
7,052,483 B2	5/2006	Wojcik	7,615,007 B2	11/2009	Shults et al.
7,056,302 B2	6/2006	Douglas	7,618,369 B2	11/2009	Hayter et al.
7,058,453 B2	6/2006	Nelson et al.	7,630,748 B2	12/2009	Budiman
7,060,031 B2	6/2006	Webb et al.	7,632,228 B2	12/2009	Brauker et al.
7,074,307 B2	7/2006	Simpson et al.	7,635,594 B2	12/2009	Holmes et al.
7,081,195 B2	7/2006	Simpson et al.	7,637,868 B2	12/2009	Saint et al.
7,082,334 B2	7/2006	Boute et al.	7,640,048 B2	12/2009	Dobbles et al.
7,092,891 B2	8/2006	Maus et al.	7,651,596 B2	1/2010	Petisce et al.
7,098,803 B2	8/2006	Mann et al.	7,651,845 B2	1/2010	Doyle, III et al.
7,108,778 B2	9/2006	Simpson et al.	7,653,425 B2	1/2010	Hayter et al.
7,110,803 B2	9/2006	Shults et al.	7,654,956 B2	2/2010	Brister et al.
7,113,821 B1	9/2006	Sun et al.	7,657,297 B2	2/2010	Simpson et al.
7,118,667 B2	10/2006	Lee	7,659,823 B1	2/2010	Killian et al.
7,123,950 B2	10/2006	Mannheimer	7,668,596 B2	2/2010	Von Arx et al.
7,125,382 B2	10/2006	Zhou et al.	7,699,775 B2	4/2010	Desai et al.
7,134,999 B2	11/2006	Brauker et al.	7,699,964 B2	4/2010	Feldman et al.
7,136,689 B2	11/2006	Shults et al.	7,711,402 B2	5/2010	Shults et al.
7,153,265 B2	12/2006	Vachon	7,713,574 B2	5/2010	Brister et al.
7,155,290 B2	12/2006	Von Arx et al.	7,715,893 B2	5/2010	Kamath et al.
7,167,818 B2	1/2007	Brown	7,736,310 B2	6/2010	Taub
7,171,274 B2	1/2007	Starkweather et al.	7,741,734 B2	6/2010	Joannopoulos et al.
7,179,226 B2	2/2007	Crothall et al.	7,766,829 B2	8/2010	Sloan et al.
7,190,988 B2	3/2007	Say et al.	7,768,386 B2	8/2010	Hayter et al.
7,192,450 B2	3/2007	Brauker et al.	7,768,387 B2	8/2010	Fennell et al.
7,198,606 B2	4/2007	Boecker et al.	7,771,352 B2	8/2010	Shults et al.
7,203,549 B2	4/2007	Schommer et al.	7,774,145 B2	8/2010	Brauker et al.
7,207,974 B2	4/2007	Safabash et al.	7,778,680 B2	8/2010	Goode et al.
7,225,535 B2	6/2007	Feldman et al.	7,779,332 B2	8/2010	Karr et al.
7,226,442 B2	6/2007	Sheppard et al.	7,782,192 B2	8/2010	Jeckelmann et al.
7,226,978 B2	6/2007	Tapsak et al.	7,783,333 B2	8/2010	Brister et al.
7,228,182 B2	6/2007	Healy et al.	7,791,467 B2	9/2010	Mazar et al.
7,237,712 B2	7/2007	DeRocco et al.	7,792,562 B2	9/2010	Shults et al.
7,258,673 B2	8/2007	Racchini et al.	7,811,231 B2	10/2010	Jin et al.
7,267,665 B2	9/2007	Steil et al.	7,813,809 B2	10/2010	Strother et al.
7,276,029 B2	10/2007	Goode, Jr. et al.	7,826,382 B2	11/2010	Sicurello et al.
7,278,983 B2	10/2007	Ireland et al.	7,826,981 B2	11/2010	Goode, Jr. et al.
7,286,894 B1	10/2007	Grant et al.	7,831,310 B2	11/2010	Lebel et al.
7,295,867 B2	11/2007	Berner et al.	7,860,574 B2	12/2010	Von Arx et al.
7,299,082 B2	11/2007	Feldman et al.	7,882,611 B2	2/2011	Shah et al.
7,310,544 B2	12/2007	Brister et al.	7,889,069 B2	2/2011	Fifolt et al.
7,317,938 B2	1/2008	Lorenz et al.	7,899,511 B2	3/2011	Shults et al.
7,318,816 B2	1/2008	Bobroff et al.	7,899,545 B2	3/2011	John
7,324,850 B2	1/2008	Persen et al.	7,905,833 B2	3/2011	Brister et al.
7,335,294 B2	2/2008	Heller et al.	7,912,674 B2	3/2011	Killoren Clark et al.
7,347,819 B2	3/2008	Lebel et al.	7,914,450 B2	3/2011	Goode, Jr. et al.
7,354,420 B2	4/2008	Steil et al.	7,916,013 B2	3/2011	Stevenson
7,364,592 B2	4/2008	Carr-Brendel et al.	7,920,906 B2	4/2011	Goode et al.
7,366,556 B2	4/2008	Brister et al.	7,928,850 B2	4/2011	Hayter et al.
7,379,765 B2	5/2008	Petisce et al.	7,938,797 B2	5/2011	Estes
7,384,397 B2	6/2008	Zhang et al.	7,941,200 B2	5/2011	Weinert et al.
7,387,010 B2	6/2008	Sunshine et al.	7,946,985 B2	5/2011	Mastrototaro et al.
7,399,277 B2	7/2008	Saidara et al.	7,955,258 B2	6/2011	Goscha et al.
7,402,153 B2	7/2008	Steil et al.	7,970,448 B2	6/2011	Shults et al.
7,404,796 B2	7/2008	Ginsberg	7,972,296 B2	7/2011	Braig et al.
7,419,573 B2	9/2008	Gundel	7,974,672 B2	7/2011	Shults et al.
7,424,318 B2	9/2008	Brister et al.	7,976,466 B2	7/2011	Ward et al.
7,460,898 B2	12/2008	Brister et al.	7,978,063 B2	7/2011	Baldus et al.
7,467,003 B2	12/2008	Brister et al.	7,996,158 B2	8/2011	Hayter et al.
7,468,125 B2	12/2008	Kraft et al.	7,999,674 B2	8/2011	Kamen
7,471,972 B2	12/2008	Rhodes et al.	8,005,524 B2	8/2011	Brauker et al.
7,474,992 B2	1/2009	Ariyur	8,010,174 B2	8/2011	Goode et al.
7,492,254 B2	2/2009	Bandy et al.	8,010,256 B2	8/2011	Oowada
7,494,465 B2	2/2009	Brister et al.	8,072,310 B1	12/2011	Everhart
			8,090,445 B2	1/2012	Ginggen
			8,093,991 B2	1/2012	Stevenson et al.
			8,094,009 B2	1/2012	Allen et al.
			8,098,159 B2	1/2012	Batra et al.



(56)

## References Cited

## U.S. PATENT DOCUMENTS

8,098,160 B2	1/2012	Howarth et al.	2003/0065308 A1	4/2003	Lebel et al.
8,098,161 B2	1/2012	Lavedas	2003/0100040 A1	5/2003	Bonnecaze et al.
8,098,201 B2	1/2012	Choi et al.	2003/0100821 A1	5/2003	Heller et al.
8,098,208 B2	1/2012	Ficker et al.	2003/0114897 A1	6/2003	Von Arx et al.
8,102,021 B2	1/2012	Degani	2003/0125612 A1	7/2003	Fox et al.
8,102,154 B2	1/2012	Bishop et al.	2003/0130616 A1	7/2003	Steil et al.
8,102,263 B2	1/2012	Yeo et al.	2003/0134347 A1	7/2003	Heller et al.
8,102,789 B2	1/2012	Rosar et al.	2003/0147515 A1	8/2003	Kai et al.
8,103,241 B2	1/2012	Young et al.	2003/0168338 A1	9/2003	Gao et al.
8,103,325 B2	1/2012	Swedlow et al.	2003/0176933 A1	9/2003	Lebel et al.
8,103,471 B2	1/2012	Hayter	2003/0187338 A1	10/2003	Say et al.
8,111,042 B2	2/2012	Bennett	2003/0191377 A1	10/2003	Robinson et al.
8,115,488 B2	2/2012	McDowell	2003/0199744 A1	10/2003	Buse et al.
8,116,681 B2	2/2012	Baarman	2003/0199790 A1	10/2003	Boecker et al.
8,116,683 B2	2/2012	Baarman	2003/0208113 A1	11/2003	Mault et al.
8,117,481 B2	2/2012	Anselmi et al.	2003/0212317 A1	11/2003	Kovatchev et al.
8,120,493 B2	2/2012	Burr	2003/0212379 A1	11/2003	Bylund et al.
8,124,452 B2	2/2012	Sheats	2003/0216630 A1	11/2003	Jersey-Willuhn et al.
8,130,093 B2	3/2012	Mazar et al.	2003/0217966 A1	11/2003	Tapsak et al.
8,131,351 B2	3/2012	Kalgren et al.	2004/0010186 A1	1/2004	Kimball et al.
8,131,365 B2	3/2012	Zhang et al.	2004/0010207 A1	1/2004	Flaherty et al.
8,131,565 B2	3/2012	Dicks et al.	2004/0011671 A1	1/2004	Shults et al.
8,132,037 B2	3/2012	Fehr et al.	2004/0024553 A1	2/2004	Monfre et al.
8,135,352 B2	3/2012	Langsweirdt et al.	2004/0039298 A1	2/2004	Abreu
8,136,735 B2	3/2012	Arai et al.	2004/0040840 A1	3/2004	Mao et al.
8,138,925 B2	3/2012	Downie et al.	2004/0041749 A1	3/2004	Dixon
8,140,160 B2	3/2012	Pless et al.	2004/0045879 A1	3/2004	Shults et al.
8,140,168 B2	3/2012	Olson et al.	2004/0054263 A1	3/2004	Moerman et al.
8,140,299 B2	3/2012	Siess	2004/0063435 A1	4/2004	Sakamoto et al.
8,150,321 B2	4/2012	Winter et al.	2004/0064068 A1	4/2004	DeNuzzio et al.
8,150,516 B2	4/2012	Levine et al.	2004/0099529 A1	5/2004	Mao et al.
8,179,266 B2	5/2012	Hermle	2004/0106858 A1	6/2004	Say et al.
8,192,394 B2	6/2012	Estes et al.	2004/0111017 A1	6/2004	Say et al.
8,216,138 B1	7/2012	McGarraugh et al.	2004/0117204 A1	6/2004	Mazar et al.
8,255,026 B1	8/2012	Al-Ali	2004/0122353 A1	6/2004	Shahmirian et al.
8,260,558 B2	9/2012	Hayter et al.	2004/0133164 A1	7/2004	Funderburk et al.
8,282,549 B2 *	10/2012	Brauker ..... A61B 5/1468 600/309	2004/0133390 A1	7/2004	Osorio et al.
8,374,668 B1	2/2013	Hayter et al.	2004/0135571 A1	7/2004	Uutela et al.
8,461,985 B2	6/2013	Fennell et al.	2004/0135684 A1	7/2004	Steinthal et al.
8,560,038 B2	10/2013	Hayter et al.	2004/0138588 A1	7/2004	Saikley et al.
8,583,205 B2	11/2013	Budiman et al.	2004/0146909 A1	7/2004	Duong et al.
8,597,570 B2	12/2013	Terashima et al.	2004/0147872 A1	7/2004	Thompson
8,600,681 B2	12/2013	Hayter et al.	2004/0152622 A1	8/2004	Keith et al.
8,710,993 B2	4/2014	Hayter et al.	2004/0167464 A1	8/2004	Ireland et al.
8,834,366 B2	9/2014	Hayter et al.	2004/0167801 A1	8/2004	Say et al.
8,845,536 B2	9/2014	Brauker et al.	2004/0171921 A1	9/2004	Say et al.
9,289,179 B2	3/2016	Hayter et al.	2004/0176672 A1	9/2004	Silver et al.
2001/0037366 A1	11/2001	Webb et al.	2004/0186362 A1	9/2004	Brauker et al.
2002/0019022 A1	2/2002	Dunn et al.	2004/0186365 A1	9/2004	Jin et al.
2002/0042090 A1	4/2002	Heller et al.	2004/0193020 A1	9/2004	Chiba et al.
2002/0054320 A1	5/2002	Ogino	2004/0193025 A1	9/2004	Steil et al.
2002/0065454 A1	5/2002	Lebel et al.	2004/0193090 A1	9/2004	Lebel et al.
2002/0068860 A1	6/2002	Clark	2004/0197846 A1	10/2004	Hockersmith et al.
2002/0072784 A1	6/2002	Sheppard et al.	2004/0199056 A1	10/2004	Husemann et al.
2002/0095076 A1	7/2002	Krausman et al.	2004/0199059 A1	10/2004	Brauker et al.
2002/0103499 A1	8/2002	Perez et al.	2004/0204687 A1	10/2004	Mogensen et al.
2002/0106709 A1	8/2002	Potts et al.	2004/0204868 A1	10/2004	Maynard et al.
2002/0117639 A1	8/2002	Paolini et al.	2004/0219664 A1	11/2004	Heller et al.
2002/0120186 A1	8/2002	Keimel	2004/0225338 A1	11/2004	Lebel et al.
2002/0128594 A1	9/2002	Das et al.	2004/0236200 A1	11/2004	Say et al.
2002/0147135 A1	10/2002	Schnell	2004/0249253 A1	12/2004	Racchini et al.
2002/0161288 A1	10/2002	Shin et al.	2004/0254433 A1	12/2004	Bandis et al.
2002/0169635 A1	11/2002	Shillingburg	2004/0254434 A1	12/2004	Goodnow et al.
2003/0004403 A1	1/2003	Drinan et al.	2004/0260478 A1	12/2004	Schwamm
2003/0023317 A1	1/2003	Brauker et al.	2004/0267300 A1	12/2004	Mace
2003/0023461 A1	1/2003	Quintanilla et al.	2005/0001024 A1	1/2005	Kusaka et al.
2003/0028089 A1	2/2003	Galley et al.	2005/0004439 A1	1/2005	Shin et al.
2003/0032077 A1	2/2003	Itoh et al.	2005/0004494 A1	1/2005	Perez et al.
2003/0032867 A1	2/2003	Crothall et al.	2005/0010269 A1	1/2005	Lebel et al.
2003/0032874 A1	2/2003	Rhodes et al.	2005/0017864 A1	1/2005	Tsoukalis
2003/0042137 A1	3/2003	Mao et al.	2005/0027177 A1	2/2005	Shin et al.
2003/0050546 A1	3/2003	Desai et al.	2005/0027180 A1	2/2005	Goode et al.
2003/0060692 A1	3/2003	Ruchti et al.	2005/0027181 A1	2/2005	Goode et al.
2003/0060753 A1	3/2003	Starkweather et al.	2005/0027462 A1	2/2005	Goode et al.
			2005/0027463 A1	2/2005	Goode et al.
			2005/0031689 A1	2/2005	Shults et al.
			2005/0038332 A1	2/2005	Saidara et al.
			2005/0043598 A1	2/2005	Goode, Jr. et al.
			2005/0049179 A1	3/2005	Davidson et al.



(56)

## References Cited

## U.S. PATENT DOCUMENTS

2005/0070774 A1	3/2005	Addison et al.	2006/0154642 A1	7/2006	Scannell
2005/0070777 A1	3/2005	Cho et al.	2006/0155180 A1	7/2006	Brister et al.
2005/0090607 A1	4/2005	Tapsak et al.	2006/0156796 A1	7/2006	Burke et al.
2005/0096511 A1	5/2005	Fox et al.	2006/0166629 A1	7/2006	Reggiardo
2005/0096512 A1	5/2005	Fox et al.	2006/0173260 A1	8/2006	Gaoni et al.
2005/0096516 A1	5/2005	Soykan et al.	2006/0173406 A1	8/2006	Hayes et al.
2005/0112169 A1	5/2005	Brauker et al.	2006/0173444 A1	8/2006	Choy et al.
2005/0113648 A1	5/2005	Yang et al.	2006/0183984 A1	8/2006	Dobbles et al.
2005/0113653 A1	5/2005	Fox et al.	2006/0183985 A1	8/2006	Brister et al.
2005/0113886 A1	5/2005	Fischell et al.	2006/0189851 A1	8/2006	Tvig et al.
2005/0114068 A1	5/2005	Chey et al.	2006/0189863 A1	8/2006	Peysen et al.
2005/0115832 A1	6/2005	Simpson et al.	2006/0193375 A1	8/2006	Lee et al.
2005/0116683 A1	6/2005	Cheng et al.	2006/0202805 A1	9/2006	Schulman et al.
2005/0121322 A1	6/2005	Say et al.	2006/0211072 A1	9/2006	Ryan et al.
2005/0131346 A1	6/2005	Douglas	2006/0222566 A1	10/2006	Brauker et al.
2005/0134731 A1	6/2005	Lee et al.	2006/0224109 A1	10/2006	Steil et al.
2005/0137530 A1	6/2005	Campbell et al.	2006/0224141 A1	10/2006	Rush et al.
2005/0143635 A1	6/2005	Kamath et al.	2006/0229512 A1	10/2006	Petisce et al.
2005/0154271 A1	7/2005	Rasdal et al.	2006/0247508 A1	11/2006	Fennell
2005/0176136 A1	8/2005	Burd et al.	2006/0247710 A1	11/2006	Goetz et al.
2005/0177398 A1	8/2005	Watanabe et al.	2006/0247985 A1	11/2006	Liamos et al.
2005/0182306 A1	8/2005	Sloan	2006/0253296 A1	11/2006	Liisberg et al.
2005/0187442 A1	8/2005	Cho et al.	2006/0258929 A1	11/2006	Goode et al.
2005/0187720 A1	8/2005	Goode, Jr. et al.	2006/0272652 A1	12/2006	Stocker et al.
2005/0192494 A1	9/2005	Ginsberg	2006/0281985 A1	12/2006	Ward et al.
2005/0192557 A1	9/2005	Brauker et al.	2006/0287691 A1	12/2006	Drew
2005/0195930 A1	9/2005	Spital et al.	2006/0290496 A1	12/2006	Peeters et al.
2005/0197793 A1	9/2005	Baker, Jr.	2006/0293607 A1	12/2006	Alt et al.
2005/0199494 A1	9/2005	Say et al.	2007/0010950 A1	1/2007	Abensour et al.
2005/0203360 A1	9/2005	Brauker et al.	2007/0016381 A1	1/2007	Kamath et al.
2005/0204134 A1	9/2005	Von Arx et al.	2007/0017983 A1	1/2007	Frank et al.
2005/0214892 A1	9/2005	Kovatchev et al.	2007/0027381 A1	2/2007	Stafford
2005/0239154 A1	10/2005	Feldman et al.	2007/0027507 A1	2/2007	Burdett et al.
2005/0239156 A1	10/2005	Drucker et al.	2007/0032706 A1	2/2007	Kamath et al.
2005/0241957 A1	11/2005	Mao et al.	2007/0032717 A1	2/2007	Brister et al.
2005/0245795 A1	11/2005	Goode et al.	2007/0033074 A1	2/2007	Nitzan et al.
2005/0245799 A1	11/2005	Brauker et al.	2007/0038044 A1	2/2007	Dobbles et al.
2005/0245839 A1	11/2005	Stivoric et al.	2007/0055799 A1	3/2007	Koehler et al.
2005/0245904 A1	11/2005	Estes et al.	2007/0060803 A1	3/2007	Liljeryd et al.
2005/0251033 A1	11/2005	Scarantino et al.	2007/0060814 A1	3/2007	Stafford
2005/0272985 A1	12/2005	Kotulla et al.	2007/0060869 A1	3/2007	Tolle et al.
2005/0277164 A1	12/2005	Drucker et al.	2007/0060979 A1	3/2007	Strother et al.
2005/0277912 A1	12/2005	John	2007/0066873 A1	3/2007	Kamath et al.
2005/0287620 A1	12/2005	Heller et al.	2007/0066956 A1	3/2007	Finkel
2006/0001538 A1	1/2006	Kraft et al.	2007/0071681 A1	3/2007	Gadkar et al.
2006/0001551 A1	1/2006	Kraft et al.	2007/0073129 A1	3/2007	Shah et al.
2006/0004270 A1	1/2006	Bedard et al.	2007/0078320 A1	4/2007	Stafford
2006/0010098 A1	1/2006	Goodnow et al.	2007/0078321 A1	4/2007	Mazza et al.
2006/0015020 A1	1/2006	Neale et al.	2007/0078322 A1	4/2007	Stafford
2006/0015024 A1	1/2006	Brister et al.	2007/0078323 A1	4/2007	Reggiardo et al.
2006/0016700 A1	1/2006	Brister et al.	2007/0078818 A1	4/2007	Zvitz et al.
2006/0017923 A1	1/2006	Ruchti et al.	2007/0093786 A1	4/2007	Goldsmith et al.
2006/0019327 A1	1/2006	Brister et al.	2007/0094216 A1	4/2007	Mathias et al.
2006/0020186 A1	1/2006	Brister et al.	2007/0100222 A1	5/2007	Mastrototaro et al.
2006/0020187 A1	1/2006	Brister et al.	2007/0106135 A1	5/2007	Sloan et al.
2006/0020188 A1	1/2006	Kamath et al.	2007/0118405 A1	5/2007	Campbell et al.
2006/0020189 A1	1/2006	Brister et al.	2007/0124002 A1	5/2007	Estes et al.
2006/0020190 A1	1/2006	Kamath et al.	2007/0129621 A1 *	6/2007	Kellogg ..... A61B 5/1486 600/365
2006/0020191 A1	1/2006	Brister et al.	2007/0149875 A1	6/2007	Ouyang et al.
2006/0020192 A1	1/2006	Brister et al.	2007/0151869 A1	7/2007	Heller et al.
2006/0020300 A1	1/2006	Nghiem et al.	2007/0156033 A1	7/2007	Causey, III et al.
2006/0025663 A1	2/2006	Talbot et al.	2007/0163880 A1	7/2007	Woo et al.
2006/0029177 A1	2/2006	Cranford et al.	2007/0168224 A1	7/2007	Letzt et al.
2006/0031094 A1	2/2006	Cohen et al.	2007/0173706 A1	7/2007	Neinast et al.
2006/0036139 A1	2/2006	Brister et al.	2007/0173709 A1	7/2007	Petisce et al.
2006/0036140 A1	2/2006	Brister et al.	2007/0173710 A1	7/2007	Petisce et al.
2006/0036141 A1	2/2006	Kamath et al.	2007/0173761 A1	7/2007	Kanderian et al.
2006/0036142 A1	2/2006	Brister et al.	2007/0179349 A1	8/2007	Hoyme et al.
2006/0036143 A1	2/2006	Brister et al.	2007/0179352 A1	8/2007	Randlov et al.
2006/0036144 A1	2/2006	Brister et al.	2007/0191701 A1	8/2007	Feldman et al.
2006/0036145 A1	2/2006	Brister et al.	2007/0191702 A1	8/2007	Yodfat et al.
2006/0058588 A1	3/2006	Zdeblick	2007/0202562 A1	8/2007	Curry et al.
2006/0079740 A1	4/2006	Silver et al.	2007/0203407 A1	8/2007	Hoss et al.
2006/0091006 A1	5/2006	Wang et al.	2007/0203966 A1	8/2007	Brauker et al.
2006/0142651 A1	6/2006	Brister et al.	2007/0208244 A1	9/2007	Brauker et al.
			2007/0208246 A1	9/2007	Brauker et al.
			2007/0213657 A1	9/2007	Jennewine et al.
			2007/0228071 A1	10/2007	Kamen et al.



(56)

## References Cited

## U.S. PATENT DOCUMENTS

2007/0232878 A1	10/2007	Kovatchev et al.	2008/0208026 A1	8/2008	Noujaim et al.
2007/0232880 A1	10/2007	Siddiqui et al.	2008/0208113 A1	8/2008	Damiano et al.
2007/0235331 A1	10/2007	Simpson et al.	2008/0214900 A1	9/2008	Fennell et al.
2007/0244383 A1	10/2007	Talbot et al.	2008/0214910 A1	9/2008	Buck
2007/0249922 A1	10/2007	Peyser et al.	2008/0214915 A1	9/2008	Brister et al.
2007/0253021 A1	11/2007	Mehta et al.	2008/0214918 A1	9/2008	Brister et al.
2007/0255321 A1	11/2007	Gerber et al.	2008/0228051 A1	9/2008	Shults et al.
2007/0255348 A1	11/2007	Holtzclaw	2008/0228054 A1	9/2008	Shults et al.
2007/0255531 A1	11/2007	Drew	2008/0228055 A1	9/2008	Sher
2007/0258395 A1	11/2007	Jollota et al.	2008/0234663 A1	9/2008	Yodfat et al.
2007/0270672 A1	11/2007	Hayter	2008/0234943 A1	9/2008	Ray et al.
2007/0271285 A1	11/2007	Eichorn et al.	2008/0235469 A1	9/2008	Drew
2007/0282299 A1	12/2007	Hellwig	2008/0242961 A1	10/2008	Brister et al.
2007/0285238 A1	12/2007	Batra	2008/0242963 A1	10/2008	Essenpreis et al.
2007/0299617 A1	12/2007	Willis	2008/0254544 A1	10/2008	Modzelewski et al.
2008/0004515 A1	1/2008	Jennewine et al.	2008/0255434 A1	10/2008	Hayter et al.
2008/0004601 A1	1/2008	Jennewine et al.	2008/0255437 A1	10/2008	Hayter
2008/0009692 A1	1/2008	Stafford	2008/0255438 A1	10/2008	Saidara et al.
2008/0017522 A1	1/2008	Heller et al.	2008/0255808 A1	10/2008	Hayter
2008/0018433 A1	1/2008	Pitt-Pladdy	2008/0256048 A1	10/2008	Hayter
2008/0021436 A1	1/2008	Wolpert et al.	2008/0262469 A1	10/2008	Brister et al.
2008/0021666 A1	1/2008	Goode, Jr. et al.	2008/0269714 A1	10/2008	Mastrototaro et al.
2008/0029391 A1	2/2008	Mao et al.	2008/0269723 A1	10/2008	Mastrototaro et al.
2008/0030369 A1	2/2008	Mann et al.	2008/0275313 A1	11/2008	Brister et al.
2008/0033254 A1	2/2008	Kamath et al.	2008/0287761 A1	11/2008	Hayter
2008/0039702 A1	2/2008	Hayter et al.	2008/0287762 A1	11/2008	Hayter
2008/0045824 A1	2/2008	Tapsak et al.	2008/0287763 A1	11/2008	Hayter
2008/0058625 A1	3/2008	McGarraugh et al.	2008/0287764 A1	11/2008	Rasdal et al.
2008/0058773 A1	3/2008	John	2008/0287765 A1	11/2008	Rasdal et al.
2008/0060955 A1	3/2008	Goodnow	2008/0287766 A1	11/2008	Rasdal et al.
2008/0061961 A1	3/2008	John	2008/0288180 A1	11/2008	Hayter
2008/0064937 A1	3/2008	McGarraugh et al.	2008/0288204 A1	11/2008	Hayter et al.
2008/0064943 A1	3/2008	Talbot et al.	2008/0294024 A1	11/2008	Cosentino et al.
2008/0071156 A1	3/2008	Brister et al.	2008/0296155 A1	12/2008	Shults et al.
2008/0071157 A1	3/2008	McGarraugh et al.	2008/0300572 A1	12/2008	Rankers et al.
2008/0071158 A1	3/2008	McGarraugh et al.	2008/0306368 A1	12/2008	Goode et al.
2008/0071328 A1	3/2008	Haubrich et al.	2008/0306434 A1	12/2008	Dobbles et al.
2008/0081977 A1	4/2008	Hayter et al.	2008/0306435 A1	12/2008	Kamath et al.
2008/0083617 A1	4/2008	Simpson et al.	2008/0306444 A1	12/2008	Brister et al.
2008/0086042 A1	4/2008	Brister et al.	2008/0312518 A1	12/2008	Jina et al.
2008/0086044 A1	4/2008	Brister et al.	2008/0312841 A1	12/2008	Hayter
2008/0086273 A1	4/2008	Shults et al.	2008/0312842 A1	12/2008	Hayter
2008/0092638 A1	4/2008	Brenneman et al.	2008/0312844 A1	12/2008	Hayter et al.
2008/0097289 A1	4/2008	Steil et al.	2008/0312845 A1	12/2008	Hayter et al.
2008/0108942 A1	5/2008	Brister et al.	2008/0314395 A1	12/2008	Kovatchev et al.
2008/0114228 A1	5/2008	McCluskey et al.	2008/0319085 A1	12/2008	Wright et al.
2008/0119705 A1	5/2008	Patel et al.	2008/0319279 A1	12/2008	Ramsay et al.
2008/0139910 A1	6/2008	Mastrototaro et al.	2009/0005665 A1	1/2009	Hayter et al.
2008/0154513 A1	6/2008	Kovatchev et al.	2009/0005666 A1	1/2009	Shin et al.
2008/0161666 A1	7/2008	Feldman et al.	2009/0005729 A1	1/2009	Hendrixson et al.
2008/0167543 A1	7/2008	Say et al.	2009/0006034 A1	1/2009	Hayter et al.
2008/0167572 A1	7/2008	Stivoric et al.	2009/0006061 A1	1/2009	Thukral et al.
2008/0172205 A1	7/2008	Breton et al.	2009/0006133 A1	1/2009	Weinert et al.
2008/0177149 A1	7/2008	Weinert et al.	2009/0012376 A1	1/2009	Agus
2008/0177165 A1	7/2008	Blomquist et al.	2009/0012379 A1	1/2009	Goode et al.
2008/0182537 A1	7/2008	Manku et al.	2009/0018424 A1	1/2009	Kamath et al.
2008/0183060 A1	7/2008	Steil et al.	2009/0018425 A1	1/2009	Ouyang et al.
2008/0183061 A1	7/2008	Goode et al.	2009/0030293 A1	1/2009	Cooper et al.
2008/0183399 A1	7/2008	Goode et al.	2009/0030294 A1	1/2009	Petisce et al.
2008/0188731 A1	8/2008	Brister et al.	2009/0033482 A1	2/2009	Hayter et al.
2008/0188796 A1	8/2008	Steil et al.	2009/0036747 A1	2/2009	Hayter et al.
2008/0189051 A1	8/2008	Goode et al.	2009/0036758 A1	2/2009	Brauker et al.
2008/0194934 A1	8/2008	Ray et al.	2009/0036760 A1	2/2009	Hayter
2008/0194935 A1	8/2008	Brister et al.	2009/0036763 A1	2/2009	Brauker et al.
2008/0194936 A1	8/2008	Goode et al.	2009/0040022 A1	2/2009	Finkenzeller
2008/0194937 A1	8/2008	Goode et al.	2009/0043181 A1	2/2009	Brauker et al.
2008/0194938 A1	8/2008	Brister et al.	2009/0043182 A1	2/2009	Brauker et al.
2008/0195232 A1	8/2008	Carr-Brendel et al.	2009/0043525 A1	2/2009	Brauker et al.
2008/0195967 A1	8/2008	Goode et al.	2009/0043541 A1	2/2009	Brauker et al.
2008/0197024 A1	8/2008	Simpson et al.	2009/0043542 A1	2/2009	Brauker et al.
2008/0200788 A1	8/2008	Brister et al.	2009/0045055 A1	2/2009	Rhodes et al.
2008/0200789 A1	8/2008	Brister et al.	2009/0048503 A1	2/2009	Dalal et al.
2008/0200791 A1	8/2008	Simpson et al.	2009/0054745 A1	2/2009	Jennewine et al.
2008/0201325 A1	8/2008	Doniger et al.	2009/0054747 A1	2/2009	Fennell
2008/0208025 A1	8/2008	Shults et al.	2009/0054748 A1	2/2009	Feldman et al.
			2009/0055149 A1	2/2009	Hayter et al.
			2009/0062633 A1	3/2009	Brauker et al.
			2009/0062635 A1	3/2009	Brauker et al.
			2009/0062767 A1	3/2009	VanAntwerp et al.



(56)

**References Cited**

## U.S. PATENT DOCUMENTS

2009/0063402 A1	3/2009	Hayter	2009/0299162 A1	12/2009	Brauker et al.
2009/0076356 A1	3/2009	Simpson et al.	2009/0299276 A1	12/2009	Brauker et al.
2009/0076360 A1	3/2009	Brister et al.	2010/0010324 A1	1/2010	Brauker et al.
2009/0076361 A1	3/2009	Kamath et al.	2010/0010329 A1	1/2010	Taub et al.
2009/0082693 A1	3/2009	Stafford	2010/0010331 A1	1/2010	Brauker et al.
2009/0085768 A1	4/2009	Patel et al.	2010/0010332 A1	1/2010	Brauker et al.
2009/0085873 A1	4/2009	Betts et al.	2010/0016687 A1	1/2010	Brauker et al.
2009/0088614 A1	4/2009	Taub et al.	2010/0016698 A1	1/2010	Rasdal et al.
2009/0093687 A1	4/2009	Telfort et al.	2010/0022855 A1	1/2010	Brauker et al.
2009/0099436 A1	4/2009	Brister et al.	2010/0022988 A1	1/2010	Wochner et al.
2009/0105554 A1	4/2009	Stahmann et al.	2010/0030038 A1	2/2010	Brauker et al.
2009/0105560 A1	4/2009	Solomon	2010/0030053 A1	2/2010	Goode, Jr. et al.
2009/0105570 A1	4/2009	Sloan et al.	2010/0030484 A1	2/2010	Brauker et al.
2009/0105571 A1	4/2009	Fennell et al.	2010/0030485 A1	2/2010	Brauker et al.
2009/0105636 A1	4/2009	Hayter et al.	2010/0036215 A1	2/2010	Goode, Jr. et al.
2009/0112478 A1	4/2009	Mueller, Jr. et al.	2010/0036216 A1	2/2010	Goode, Jr. et al.
2009/0124877 A1	5/2009	Goode et al.	2010/0036222 A1	2/2010	Goode, Jr. et al.
2009/0124878 A1	5/2009	Goode et al.	2010/0036223 A1	2/2010	Goode, Jr. et al.
2009/0124879 A1	5/2009	Brister et al.	2010/0036225 A1	2/2010	Goode, Jr. et al.
2009/0124964 A1	5/2009	Leach et al.	2010/0041971 A1	2/2010	Goode, Jr. et al.
2009/0131768 A1	5/2009	Simpson et al.	2010/0045465 A1	2/2010	Brauker et al.
2009/0131769 A1	5/2009	Leach et al.	2010/0049024 A1	2/2010	Saint et al.
2009/0131776 A1	5/2009	Simpson et al.	2010/0056992 A1	3/2010	Hayter et al.
2009/0131777 A1	5/2009	Simpson et al.	2010/0057040 A1	3/2010	Hayter
2009/0137886 A1	5/2009	Shariati et al.	2010/0057041 A1	3/2010	Hayter
2009/0137887 A1	5/2009	Shariati et al.	2010/0057042 A1	3/2010	Hayter
2009/0143659 A1	6/2009	Li et al.	2010/0057044 A1	3/2010	Hayter
2009/0143660 A1	6/2009	Brister et al.	2010/0057057 A1	3/2010	Hayter et al.
2009/0150186 A1	6/2009	Cohen et al.	2010/0063373 A1	3/2010	Kamath et al.
2009/0156919 A1	6/2009	Brister et al.	2010/0076283 A1	3/2010	Simpson et al.
2009/0156924 A1	6/2009	Shariati et al.	2010/0081906 A1	4/2010	Hayter et al.
2009/0163790 A1	6/2009	Brister et al.	2010/0081908 A1	4/2010	Dobbles et al.
2009/0163791 A1	6/2009	Brister et al.	2010/0081909 A1	4/2010	Budiman et al.
2009/0163855 A1	6/2009	Shin et al.	2010/0081910 A1	4/2010	Brister et al.
2009/0164190 A1	6/2009	Hayter	2010/0081953 A1	4/2010	Syeda-Mahmood et al.
2009/0164239 A1	6/2009	Hayter et al.	2010/0087724 A1	4/2010	Brauker et al.
2009/0164251 A1	6/2009	Hayter	2010/0094251 A1	4/2010	Estes et al.
2009/0177068 A1	7/2009	Stivoric et al.	2010/0096259 A1	4/2010	Zhang et al.
2009/0178459 A1	7/2009	Li et al.	2010/0099970 A1	4/2010	Shults et al.
2009/0182217 A1	7/2009	Li et al.	2010/0099971 A1	4/2010	Shults et al.
2009/0189738 A1	7/2009	Hermle	2010/0105999 A1	4/2010	Dixon et al.
2009/0192366 A1	7/2009	Mensinger et al.	2010/0119693 A1	5/2010	Tapsak et al.
2009/0192380 A1	7/2009	Shariati et al.	2010/0121167 A1	5/2010	McGarraugh et al.
2009/0192722 A1	7/2009	Shariati et al.	2010/0121169 A1	5/2010	Petisce et al.
2009/0192724 A1	7/2009	Brauker et al.	2010/0141656 A1	6/2010	Krieffewirth
2009/0192745 A1	7/2009	Kamath et al.	2010/0152554 A1	6/2010	Steine et al.
2009/0192751 A1	7/2009	Kamath et al.	2010/0160759 A1	6/2010	Celentano et al.
2009/0198118 A1	8/2009	Hayter et al.	2010/0168538 A1	7/2010	Keenan et al.
2009/0203981 A1	8/2009	Brauker et al.	2010/0168546 A1	7/2010	Kamath et al.
2009/0204341 A1	8/2009	Brauker et al.	2010/0174266 A1	7/2010	Estes
2009/0216100 A1	8/2009	Ebner et al.	2010/0185175 A1	7/2010	Kamen et al.
2009/0216103 A1	8/2009	Brister et al.	2010/0190435 A1	7/2010	Cook et al.
2009/0227855 A1	9/2009	Hill et al.	2010/0191082 A1	7/2010	Brister et al.
2009/0234200 A1	9/2009	Husheer	2010/0191085 A1	7/2010	Budiman
2009/0240120 A1	9/2009	Mensinger et al.	2010/0191472 A1	7/2010	Doniger et al.
2009/0240128 A1	9/2009	Mensinger et al.	2010/0198142 A1	8/2010	Sloan et al.
2009/0240193 A1	9/2009	Mensinger et al.	2010/0204557 A1	8/2010	Kiaie et al.
2009/0240440 A1	9/2009	Shurabura et al.	2010/0213080 A1	8/2010	Celentano et al.
2009/0242399 A1	10/2009	Kamath et al.	2010/0234710 A1	9/2010	Budiman et al.
2009/0242425 A1	10/2009	Kamath et al.	2010/0240975 A1	9/2010	Goode et al.
2009/0247855 A1	10/2009	Boock et al.	2010/0274111 A1	10/2010	Say et al.
2009/0247856 A1	10/2009	Boock et al.	2010/0274515 A1	10/2010	Hoss et al.
2009/0247857 A1	10/2009	Harper et al.	2010/0312176 A1	12/2010	Lauer et al.
2009/0247931 A1	10/2009	Damgaard-Sorensen	2010/0313105 A1	12/2010	Nekoomaram et al.
2009/0253973 A1	10/2009	Bashan et al.	2011/0004085 A1	1/2011	Mensinger et al.
2009/0259118 A1	10/2009	Feldman et al.	2011/0004276 A1	1/2011	Blair et al.
2009/0267765 A1	10/2009	Greene et al.	2011/0024043 A1	2/2011	Boock et al.
2009/0287073 A1	11/2009	Boock et al.	2011/0024307 A1	2/2011	Simpson et al.
2009/0287074 A1	11/2009	Shults et al.	2011/0027127 A1	2/2011	Simpson et al.
2009/0289796 A1	11/2009	Blumberg	2011/0027453 A1	2/2011	Boock et al.
2009/0292188 A1	11/2009	Hoss et al.	2011/0027458 A1	2/2011	Boock et al.
2009/0296742 A1	12/2009	Sicurello et al.	2011/0028815 A1	2/2011	Simpson et al.
2009/0298182 A1	12/2009	Schulat et al.	2011/0028816 A1	2/2011	Simpson et al.
2009/0299155 A1	12/2009	Yang et al.	2011/0031986 A1	2/2011	Bhat et al.
2009/0299156 A1	12/2009	Simpson et al.	2011/0040163 A1	2/2011	Telson et al.
			2011/0077490 A1	3/2011	Simpson et al.
			2011/0077494 A1	3/2011	Doniger et al.
			2011/0081726 A1	4/2011	Berman et al.
			2011/0112696 A1	5/2011	Yodfat et al.



(56)

## References Cited

## U.S. PATENT DOCUMENTS

2011/0148905 A1 6/2011 Simmons et al.  
 2011/0152637 A1 6/2011 Kateraas et al.  
 2011/0208027 A1 8/2011 Wagner et al.  
 2011/0257895 A1 10/2011 Brauker et al.  
 2011/0282327 A1 11/2011 Kellogg et al.  
 2011/0287528 A1 11/2011 Fern et al.  
 2011/0289497 A1 11/2011 Kiaie et al.  
 2011/0320130 A1 12/2011 Valdes et al.  
 2011/0320167 A1 12/2011 Budiman  
 2012/0078071 A1 3/2012 Bohm et al.  
 2012/0108934 A1 5/2012 Valdes et al.  
 2012/0165626 A1 6/2012 Irina et al.  
 2012/0165640 A1 6/2012 Galley et al.  
 2012/0173200 A1 7/2012 Breton et al.  
 2013/0035575 A1 2/2013 Mayou et al.  
 2013/0235166 A1 9/2013 Jones et al.

## FOREIGN PATENT DOCUMENTS

CA 2413148 8/2010  
 DE 4401400 7/1995  
 EP 0098592 1/1984  
 EP 0127958 12/1984  
 EP 0320109 6/1989  
 EP 0353328 2/1990  
 EP 0390390 10/1990  
 EP 0396788 11/1990  
 EP 0286118 1/1995  
 EP 0724859 8/1996  
 EP 0678308 5/2000  
 EP 1048264 11/2000  
 EP 1292218 3/2003  
 EP 1077634 7/2003  
 EP 1568309 8/2005  
 EP 1666091 6/2006  
 EP 1703697 9/2006  
 EP 1704893 9/2006  
 EP 1897487 11/2009  
 EP 1897492 11/2009  
 EP 2113864 11/2009  
 EP 1897488 12/2009  
 EP 1681992 4/2010  
 EP 1448489 8/2010  
 EP 1971396 8/2010  
 EP 2201969 3/2011  
 EP 2153382 2/2012  
 EP 2284773 2/2012  
 GB 2409951 7/2005  
 WO WO-93/06237 4/1993  
 WO WO-96/25089 8/1996  
 WO WO-96/35370 11/1996  
 WO WO-97/33513 9/1997  
 WO WO-98/35053 8/1998  
 WO WO-99/56613 11/1999  
 WO WO-00/49940 8/2000  
 WO WO-00/59370 10/2000  
 WO WO-00/74753 12/2000  
 WO WO-00/78992 12/2000  
 WO WO-01/52935 7/2001  
 WO WO-01/54753 8/2001  
 WO WO-02/16905 2/2002  
 WO WO-02/058537 8/2002  
 WO WO-03/076893 9/2003  
 WO WO-03/082091 10/2003  
 WO WO-03/085372 10/2003  
 WO WO-2004/047445 6/2004  
 WO WO-2004/061420 7/2004  
 WO WO-2005/010756 2/2005  
 WO WO-2005/040404 5/2005  
 WO WO-2005/041766 5/2005  
 WO WO-2005/045744 5/2005  
 WO WO-2005/089103 9/2005  
 WO WO-2005/119238 12/2005  
 WO WO-2006/024671 3/2006  
 WO WO-2006/032653 3/2006

WO WO-2006/051466 5/2006  
 WO WO-2006/064397 6/2006  
 WO WO-2006/079114 7/2006  
 WO WO-2006/118947 11/2006  
 WO WO-2006/124099 11/2006  
 WO WO-2007/007459 1/2007  
 WO WO-2007/016399 2/2007  
 WO WO-2007/027788 3/2007  
 WO WO-2007/041069 4/2007  
 WO WO-2007/041070 4/2007  
 WO WO-2007/041248 4/2007  
 WO WO-2007/056638 5/2007  
 WO WO-2007/097754 8/2007  
 WO WO-2007/101223 9/2007  
 WO WO-2007/120363 10/2007  
 WO WO-2007/126444 11/2007  
 WO WO-2007/053832 12/2007  
 WO WO-2007/143225 12/2007  
 WO WO-2008/021913 2/2008  
 WO WO-2008/042760 4/2008  
 WO WO-2008/086541 7/2008  
 WO WO-2008/128210 10/2008  
 WO WO-2008/130896 10/2008  
 WO WO-2008/130897 10/2008  
 WO WO-2008/130898 10/2008  
 WO WO-2008/143943 11/2008  
 WO WO-2008/151452 12/2008  
 WO WO-2009/018058 2/2009  
 WO WO-2009/049252 4/2009  
 WO WO-2009/086216 7/2009  
 WO WO-2009/096992 8/2009  
 WO WO-2009/097594 8/2009  
 WO WO-2010/077329 7/2010  
 WO WO-2011/022418 2/2011

## OTHER PUBLICATIONS

Steil, G. M., et al., "Closed-Loop Insulin Delivery—the Path of Physiological Glucose Control", *Advanced Drug Delivery Reviews*, vol. 56, 2004, pp. 125-144.  
 Steil, G. M., et al., "Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor", *Diabetes Technology & Therapeutics*, vol. 5, No. 1, 2003, pp. 27-31.  
 U.S. Appl. No. 11/831,895, Office Action dated Mar. 21, 2016.  
 U.S. Appl. No. 12/102,847, Office Action dated Aug. 3, 2015.  
 U.S. Appl. No. 12/102,847, Office Action dated Dec. 31, 2015.  
 U.S. Appl. No. 12/102,847, Office Action dated Feb. 12, 2015.  
 U.S. Appl. No. 12/102,855, Office Action dated Mar. 23, 2016.  
 U.S. Appl. No. 12/102,855, Office Action dated May 13, 2015.  
 U.S. Appl. No. 12/102,855, Office Action dated Sep. 2, 2015.  
 U.S. Appl. No. 12/152,662, Office Action dated Aug. 19, 2015.  
 U.S. Appl. No. 12/152,662, Office Action dated Mar. 9, 2016.  
 U.S. Appl. No. 13/925,685, Office Action dated May 16, 2016.  
 U.S. Appl. No. 14/472,341, Notice of Allowance dated Mar. 28, 2016.  
 U.S. Appl. No. 14/472,341, Office Action dated Oct. 9, 2015.  
 Kovatchev, B. P., et al., "Graphical and Numerical Evaluation of Continuous Glucose Sensing Time Lag", *Diabetes Technology & Therapeutics*, vol. 11, No. 3, 2009, pp. 139-143.  
 European Patent Application No. 08745809.7, Examination Report dated Aug. 16, 2016.  
 U.S. Appl. No. 13/898,139, Notice of Allowance dated Sep. 15, 2016.  
 U.S. Appl. No. 13/925,685, Notice of Allowance dated Sep. 20, 2016.  
 U.S. Appl. No. 14/077,004, Office Action dated Jul. 26, 2016.  
 U.S. Appl. No. 14/094,721, Office Action dated Jun. 30, 2016.  
 U.S. Appl. No. 14/052,381, Office Action dated Oct. 3, 2016.  
 U.S. Appl. No. 14/094,721, Advisory Action dated Sep. 28, 2016.  
 Armour, J. C., et al., "Application of Chronic Intravascular Blood Glucose Sensor in Dogs", *Diabetes*, vol. 39, 1990, pp. 1519-1526.  
 Aussedat, B., et al., "A User-Friendly Method for Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycemic Alarm", *Biosensors & Bioelectronics*, vol. 12, No. 11, 1997, pp. 1061-1070.



(56)

## References Cited

## OTHER PUBLICATIONS

- Bennion, N., et al., "Alternate Site Glucose Testing: A Crossover Design", *Diabetes Technology & Therapeutics*, vol. 4, No. 1, 2002, pp. 25-33.
- Blank, T. B., et al., "Clinical Results From a Non-Invasive Blood Glucose Monitor", *Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II. Proceedings of SPIE*, vol. 4624, 2002, pp. 1-10.
- Bremer, T. M., et al., "Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies", *Diabetes Technology & Therapeutics*, vol. 3, 2001, pp. 409-418.
- Brooks, S. L., "Development of an On-Line Glucose Sensor for Fermentation Monitoring", *Biosensors*, vol. 3, 1987/88, pp. 45-56.
- Cass, A. E., "Ferrocene-Mediated Enzyme Electrode for Amperometric Determination of Glucose", *Analytical Chemistry*, vol. 56, No. 4, 1984, 667-671.
- Cheyne, E. H., et al., "Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers", *Diabetes Technology & Therapeutics*, vol. 4, No. 5, 2002, pp. 607-613.
- Csoregi, E., et al., "Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on 'Wired' Glucose Oxidase", *Analytical Chemistry*, vol. 67, No. 7, 1995, pp. 1240-1244.
- El-Khatib, F. H. et al., "Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine", *Journal of Diabetes and Science and Technology*, vol. 1, No. 2, 2007, pp. 181-192.
- Feldman, B., et al., "A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes", *Diabetes Technology & Therapeutics*, vol. 5, No. 5, 2003, pp. 769-779.
- Feldman, B., et al., "Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change", *Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet*, 2004.
- Garg, S., et al., "Improvement in Glycemic Excursions with a Transcutaneous, Real-Time Continuous Glucose Sensor", *Diabetes Care*, vol. 29, No. 1, 2006, pp. 44-50.
- Isermann, R., "Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction", *Control Engineering Practice*, vol. 5, No. 5, 1997, pp. 639-652.
- Iserman, R., et al., "Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes", *Control Engineering Practice*, vol. 5, 1997, pp. 709-719.
- Johnson, P. C., "Peripheral Circulation", *John Wiley & Sons*, 1978, pp. 198.
- Jungheim, K., et al., "How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type I Diabetes?", 2002, pp. 250.
- Jungheim, K., et al., "Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm", *Diabetes Care*, vol. 24, No. 7, 2001, pp. 1303-1304.
- Kaplan, S. M., "Wiley Electrical and Electronics Engineering Dictionary", *IEEE Press*, 2004, pp. 141, 142, 548, 549.
- Kuure-Kinsey, M., et al., "A Dual-Rate Kalman Filter for Continuous Glucose Monitoring", *Proceedings of the 28th IEEE, EMBS Annual International Conference*, New York City, 2006, pp. 63-66.
- Lo, B., et al., "Key Technical Challenges and Current Implementations of Body Sensor Networks", *Body Sensor Networks*, 2005, pp. 1-5.
- Lodwig, V., et al., "Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria", *Diabetes Technology & Therapeutics*, vol. 5, No. 4, 2003, pp. 573-587.
- Lortz, J., et al., "What is Bluetooth? We Explain The Newest Short-Range Connectivity Technology", *Smart Computing Learning Series, Wireless Computing*, vol. 8, Issue 5, 2002, pp. 72-74.
- Malin, S. F., et al., "Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy", *Clinical Chemistry*, vol. 45, No. 9, 1999, pp. 1651-1658.
- McGarraugh, G., et al., "Glucose Measurements Using Blood Extracted from the Forearm and the Finger", *TheraSense, Inc.*, 2001, 16 Pages.
- McGarraugh, G., et al., "Physiological Influences on Off-Finger Glucose Testing", *Diabetes Technology & Therapeutics*, vol. 3, No. 3, 2001, pp. 367-376.
- McKean, B. D., et al., "A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors", *IEEE Transactions on Biomedical Engineering*, vol. 35, No. 7, 1988, pp. 526-532.
- Morbideucci, U, et al., "Improved Usability of the Minimal Model of Insulin Sensitivity Based on an Automated Approach and Genetic Algorithms for Parameter Estimation", *Clinical Science*, vol. 112, 2007, pp. 257-263.
- Mougiakakou, et al., "A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients", *Proceedings of the 2005 IEEE*, 2005, pp. 298-301.
- Pantoleon, A. E., et al., "The Role of the Independent Variable to Glucose Sensor Calibration", *Diabetes Technology & Therapeutics*, vol. 5, No. 3, 2003, pp. 401-410.
- Parker, R., et al., "Robust H $\infty$  Glucose Control in Diabetes Using a Physiological Model", *AIChE Journal*, vol. 46, No. 12, 2000, pp. 2537-2549.
- Pickup, J., et al., "Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy", *Biosensors*, vol. 3, 1987/88, pp. 335-346.
- Pickup, J., et al., "In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer", *Diabetologia*, vol. 32, 1989, pp. 213-217.
- Pishko, M. V., et al., "Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels", *Analytical Chemistry*, vol. 63, No. 20, 1991, pp. 2268-2272.
- Quinn, C. P., et al., "Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors", *The American Physiological Society*, 1995, E155-E161.
- Rodriguez, N., et al., "Flexible Communication and Control Protocol for Injectable Neuromuscular Interfaces", *IEEE Transactions on Biomedical Circuits and Systems*, vol. I, No. 1, 2007, pp. 19-27.
- Roe, J. N., et al., "Bloodless Glucose Measurements", *Critical Review in Therapeutic Drug Carrier Systems*, vol. 15, Issue 3, 1998, pp. 199-241.
- Sakakida, M., et al., "Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations", *Artificial Organs Today*, vol. 2, No. 2, 1992, pp. 145-158.
- Sakakida, M., et al., "Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane", *Sensors and Actuators B*, vol. 13-14, 1993, pp. 319-322.
- Salehi, C., et al., "A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors", *Analytical Letters*, vol. 29, No. 13, 1996, pp. 2289-2308.
- Schmidtke, D. W., et al., "Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin", *Proceedings of the National Academy of Sciences*, vol. 95, 1998, pp. 294-299.
- Shaw, G. W., et al., "In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients", *Biosensors & Bioelectronics*, vol. 6, 1991, pp. 401-406.
- Shichiri, M., et al., "Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas", *Diabetologia*, vol. 24, 1983, pp. 179-184.
- Shichiri, M., et al., "In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers", *Hormone and Metabolic Research Supplement Series*, vol. 20, 1988, pp. 17-20.
- Shichiri, M., et al., "Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor", *Diabetes Nutrition and Metabolism*, vol. 2, 1989, pp. 309-313.
- Shichiri, M., et al., "Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas", *Implantable Sensors for Closed-Loop Prosthetic Systems*, Chapter 15, 1985, pp. 197-210.



(56)

**References Cited**

## OTHER PUBLICATIONS

Shichiri, M., et al., "Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in a Diabetic Individuals", *Diabetes Care*, vol. 9, No. 3, 1986, pp. 298-301.

Shichiri, M., et al., "Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor", *The Lancet*, 1982, pp. 1129-1131.

Shults, M. C., et al., "A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors", *IEEE Transactions on Biomedical Engineering*, vol. 41, No. 10, 1994, pp. 937-942.

Sternberg, R., et al., "Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors", *Biosensors*, vol. 4, 1988, pp. 27-40.

Thompson, M., et al., "In Vivo Probes: Problems and Perspectives", *Clinical Biochemistry*, vol. 19, 1986, pp. 255-261.

Turner, A., et al., "Diabetes Mellitus: Biosensors for Research and Management", *Biosensors*, vol. 1, 1985, pp. 85-115.

Updike, S. J., et al., "Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)", *Biosensors in the Body: Contrinuous in vivo Monitoring*, Chapter 4, 1997, pp. 117-137.

Velho, G., et al., "Strategies for Calibrating a Subcutaneous Glucose Sensor", *Biomedica Biochimica Acta*, vol. 48, 1989, pp. 957-964.

Wilson, G. S., et al., "Progress Toward the Development of an Implantable Sensor for Glucose", *Clinical Chemistry*, vol. 38, No. 9, 1992, pp. 1613-1617.

European Patent Application No. 08745803.0, Extended European Search Report dated Sep. 27, 2012.

European Patent Application No. 08745805.5, Extended European Search Report dated May 23, 2012.

European Patent Application No. 08745807.1, Extended European Search Report dated Oct. 8, 2012.

European Patent Application No. 08745809.7, Extended European Search Report dated Jul. 2, 2012.

European Patent Application No. 08754499.5, Extended European Search Report dated Sep. 20, 2012.

European Patent Application No. 08871628.7, Extended European Search Report dated Oct. 15, 2012.

PCT Application No. PCT/US2008/006247, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Nov. 26, 2009.

PCT Application No. PCT/US2008/006247, International Search Report and Written Opinion of the International Searching Authority dated Sep. 5, 2008.

PCT Application No. PCT/US2008/060277, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Oct. 29, 2009.

PCT Application No. PCT/US2008/060277, International Search Report and Written Opinion of the International Searching Authority dated Sep. 22, 2008.

PCT Application No. PCT/US2008/060279, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Oct. 29, 2009.

PCT Application No. PCT/US2008/060279, International Search Report and Written Opinion of the International Searching Authority dated Jul. 14, 2008.

PCT Application No. PCT/US2008/060281, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Oct. 29, 2009.

PCT Application No. PCT/US2008/060281, International Search Report and Written Opinion of the International Searching Authority dated Sep. 23, 2008.

PCT Application No. PCT/US2008/060282, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Oct. 29, 2009.

PCT Application No. PCT/US2008/060282, International Search Report and Written Opinion of the International Searching Authority dated Jun. 18, 2009.

PCT Application No. PCT/US2008/060284, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Oct. 29, 2009.

PCT Application No. PCT/US2008/060284, International Search Report and Written Opinion of the International Searching Authority dated Sep. 23, 2008.

PCT Application No. PCT/US2008/070923, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Feb. 11, 2010.

PCT Application No. PCT/US2008/070923, International Search Report and Written Opinion of the International Searching Authority dated Oct. 1, 2008.

U.S. Appl. No. 11/831,866, Notice of Allowance dated May 26, 2010.

U.S. Appl. No. 11/831,866, Office Action dated Jun. 25, 2009.

U.S. Appl. No. 11/831,866, Supplemental Office Action dated Dec. 9, 2009.

U.S. Appl. No. 11/831,881, Advisory Action dated Aug. 23, 2013.

U.S. Appl. No. 11/831,881, Office Action dated Jun. 21, 2011.

U.S. Appl. No. 11/831,881, Office Action dated Nov. 17, 2011.

U.S. Appl. No. 11/831,881, Office Action dated Oct. 1, 2012.

U.S. Appl. No. 11/831,895, Advisory Action dated Aug. 5, 2013.

U.S. Appl. No. 11/831,895, Advisory Action dated Jan. 18, 2012.

U.S. Appl. No. 11/831,895, Advisory Action dated Jan. 25, 2012.

U.S. Appl. No. 11/831,895, Office Action dated Jul. 20, 2012.

U.S. Appl. No. 11/831,895, Office Action dated May 16, 2013.

U.S. Appl. No. 11/831,895, Office Action dated May 25, 2011.

U.S. Appl. No. 11/831,895, Office Action dated Oct. 1, 2013.

U.S. Appl. No. 11/831,895, Office Action dated Oct. 14, 2011.

U.S. Appl. No. 12/102,839, Advisory Action dated May 1, 2013.

U.S. Appl. No. 12/102,839, Office Action dated Aug. 1, 2013.

U.S. Appl. No. 12/102,839, Office Action dated Aug. 5, 2010.

U.S. Appl. No. 12/102,839, Office Action dated Dec. 14, 2009.

U.S. Appl. No. 12/102,839, Office Action dated Dec. 14, 2012.

U.S. Appl. No. 12/102,839, Office Action dated Dec. 5, 2013.

U.S. Appl. No. 12/102,839, Office Action dated Jan. 25, 2011.

U.S. Appl. No. 12/102,839, Office Action dated May 25, 2012.

U.S. Appl. No. 12/102,839, Office Action dated Oct. 27, 2011.

U.S. Appl. No. 12/102,844, Notice of Allowance dated Jan. 10, 2012.

U.S. Appl. No. 12/102,844, Office Action dated Aug. 17, 2011.

U.S. Appl. No. 12/102,847, Office Action dated Aug. 18, 2011.

U.S. Appl. No. 12/102,847, Office Action dated Jan. 10, 2012.

U.S. Appl. No. 12/102,855, Office Action dated Aug. 24, 2011.

U.S. Appl. No. 12/102,855, Office Action dated Jan. 10, 2012.

U.S. Appl. No. 12/102,856, Office Action dated Aug. 17, 2011.

U.S. Appl. No. 12/102,856, Office Action dated Jan. 10, 2012.

U.S. Appl. No. 12/152,623, Notice of Allowance dated Nov. 3, 2011.

U.S. Appl. No. 12/152,623, Office Action dated May 26, 2011.

U.S. Appl. No. 12/152,636, Office Action dated Jan. 19, 2012.

U.S. Appl. No. 12/152,636, Office Action dated Jan. 6, 2012.

U.S. Appl. No. 12/152,636, Notice of Allowance dated Jun. 19, 2012.

U.S. Appl. No. 12/152,636, Office Action dated Dec. 27, 2010.

U.S. Appl. No. 12/152,636, Office Action dated Sep. 20, 2011.

U.S. Appl. No. 12/152,648, Notice of Allowance dated Aug. 2, 2013.

U.S. Appl. No. 12/152,648, Office Action dated Aug. 12, 2011.

U.S. Appl. No. 12/152,648, Office Action dated Aug. 29, 2012.

U.S. Appl. No. 12/152,648, Office Action dated Jan. 27, 2012.

U.S. Appl. No. 12/152,648, Office Action dated Mar. 13, 2013.

U.S. Appl. No. 12/152,649, Notice of Allowance dated Jul. 1, 2013.

U.S. Appl. No. 12/152,649, Office Action dated Aug. 5, 2011.

U.S. Appl. No. 12/152,649, Office Action dated Jan. 27, 2012.

U.S. Appl. No. 12/152,649, Office Action dated Nov. 5, 2012.

U.S. Appl. No. 12/152,650, Notice of Allowance dated Jan. 22, 2013.

U.S. Appl. No. 12/152,650, Office Action dated Aug. 11, 2011.

U.S. Appl. No. 12/152,650, Office Action dated Jan. 26, 2012.

U.S. Appl. No. 12/152,650, Office Action dated Jul. 25, 2012.

U.S. Appl. No. 12/152,652, Advisory Action dated Jan. 13, 2012.

U.S. Appl. No. 12/152,652, Notice of Allowance dated May 3, 2012.



(56)

**References Cited**

## OTHER PUBLICATIONS

U.S. Appl. No. 12/152,652, Office Action dated Jun. 23, 2011.  
 U.S. Appl. No. 12/152,652, Office Action dated Nov. 1, 2011.  
 U.S. Appl. No. 12/152,652, Office Action dated Aug. 11, 2011.  
 U.S. Appl. No. 12/152,657, Office Action dated Jan. 26, 2012.  
 U.S. Appl. No. 12/152,662, Office Action dated Aug. 19, 2011.  
 U.S. Appl. No. 12/152,662, Office Action dated Jan. 11, 2012.  
 U.S. Appl. No. 12/152,670, Notice of Allowance dated Jun. 20, 2011.  
 U.S. Appl. No. 12/152,670, Office Action dated Jan. 7, 2011.  
 U.S. Appl. No. 12/152,673, Advisory Action dated Apr. 9, 2013.  
 U.S. Appl. No. 12/512,673, Office Action dated Aug. 26, 2011.  
 U.S. Appl. No. 12/152,673, Office Action dated Jan. 30, 2013.  
 U.S. Appl. No. 12/152,673, Office Action dated Jan. 5, 2012.  
 U.S. Appl. No. 12/152,673, Office Action dated Jul. 11, 2012.  
 U.S. Appl. No. 13/356,598, Notice of Allowance dated Jul. 11, 2013.  
 U.S. Appl. No. 13/356,598, Office Action dated Aug. 30, 2012.  
 U.S. Appl. No. 13/356,598, Office Action dated May 2, 2013.  
 U.S. Appl. No. 13/567,038, Notice of Allowance dated Nov. 22, 2013.  
 U.S. Appl. No. 13/567,038, Office Action dated Jun. 6, 2013.  
 U.S. Appl. No. 13/567,038, Office Action dated Oct. 10, 2013.  
 U.S. Appl. No. 13/599,847, Notice of Allowance dated Aug. 21, 2013.  
 U.S. Appl. No. 13/599,847, Office Action dated Jan. 29, 2013.  
 Arnold, M. A., et al., "Selectivity Assessment of Noninvasive Glucose Measurements Based on Analysis of Multivariate Calibration Vectors", *Journal of Diabetes Science and Technology*, vol. 1, No. 4, 2007, pp. 454-462.  
 Boyne, M. S., et al., "Timing of Changes in Intersitil and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor", *Diabetes*, vol. 52, Nov. 2003, pp. 2790-2794.  
 Eren-Oruklu, M., et al., "Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models", *Diabetes Technology & Therapeutics* vol. 11(4), 2009, pp. 243-253.  
 Li, Y., et al., "In Vivo Release From a Drug Delivery MEMS Device", *Journal of Controlled Release*, vol. 100, 204, pp. 211-219.  
 Canadian Patent Application No. 2,683,930, Examiner's Report dated Aug. 17, 2015.  
 Canadian Patent Application No. 2,683,930, Examiner's Report dated Jul. 22, 2014.  
 European Patent Application No. 08745805.5, Examination Report dated Jan. 30, 2015.  
 European Patent Application No. 08796500.0, Examination Report dated Dec. 4, 2014.  
 European Patent Application No. 08796500.0, Extended European Search Report dated Jan. 14, 2014.  
 PCT Application No. PCT/US2009/032756, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, dated Aug. 12, 2010.  
 PCT Application No. PCT/US2009/032756, International Search Report and Written Opinion of the International Searching Authority dated Apr. 7, 2009.

U.S. Appl. No. 11/831,881, Notice of Allowance dated Jun. 20, 2014.  
 U.S. Appl. No. 11/831,881, Office Action dated Mar. 13, 2014.  
 U.S. Appl. No. 11/831,881, Office Action dated May 23, 2013.  
 U.S. Appl. No. 11/831,895, Advisory Action dated Apr. 22, 2015.  
 U.S. Appl. No. 11/831,895, Office Action dated Feb. 13, 2015.  
 U.S. Appl. No. 11/831,895, Office Action dated Jul. 17, 2014.  
 U.S. Appl. No. 12/024,101, Notice of Allowance dated Jan. 9, 2012.  
 U.S. Appl. No. 12/024,101, Office Action dated Feb. 17, 2011.  
 U.S. Appl. No. 12/024,101, Office Action dated Oct. 17, 2011.  
 U.S. Appl. No. 12/102,839, Notice of Allowance dated Oct. 30, 2015.  
 U.S. Appl. No. 12/102,839, Office Action dated Jul. 17, 2015.  
 U.S. Appl. No. 12/102,847, Advisory Action dated Aug. 27, 2014.  
 U.S. Appl. No. 12/102,847, Office Action dated Apr. 24, 2014.  
 U.S. Appl. No. 12/102,847, Office Action dated Jun. 16, 2014.  
 U.S. Appl. No. 12/102,855, Office Action dated Jun. 11, 2014.  
 U.S. Appl. No. 12/102,855, Office Action dated Oct. 24, 2014.  
 U.S. Appl. No. 12/102,856, Notice of Allowance dated Feb. 25, 2015.  
 U.S. Appl. No. 12/102,856, Office Action dated May 7, 2014.  
 U.S. Appl. No. 12/102,856, Office Action dated Nov. 25, 2014.  
 U.S. Appl. No. 12/152,657, Notice of Allowance dated Jul. 10, 2015.  
 U.S. Appl. No. 12/152,657, Office Action dated Apr. 24, 2015.  
 U.S. Appl. No. 12/152,657, Office Action dated Sep. 18, 2014.  
 U.S. Appl. No. 12/152,662, Advisory Action dated Sep. 3, 2014.  
 U.S. Appl. No. 12/152,662, Office Action dated Jan. 23, 2015.  
 U.S. Appl. No. 12/152,662, Office Action dated Jun. 12, 2014.  
 U.S. Appl. No. 13/424,291, Notice of Allowance dated Apr. 24, 2013.  
 U.S. Appl. No. 13/424,291, Office Action dated Feb. 6, 2013.  
 U.S. Appl. No. 13/424,291, Office Action dated Jul. 31, 2012.  
 U.S. Appl. No. 13/898,139, Office Action dated Jan. 21, 2016.  
 U.S. Appl. No. 14/094,721, Office Action dated Feb. 25, 2016.  
 U.S. Appl. No. 14/106,000, Notice of Allowance dated Apr. 24, 2015.  
 U.S. Appl. No. 14/106,000, Office Action dated Aug. 26, 2014.  
 U.S. Appl. No. 14/106,000, Office Action dated Jun. 17, 2014.  
 U.S. Appl. No. 14/106,000, Office Action dated Nov. 26, 2014.  
 U.S. Appl. No. 14/472,341, Office Action dated Apr. 10, 2015.  
 U.S. Appl. No. 14/472,341, Office Action dated Dec. 23, 2014.  
 U.S. Appl. No. 14/741,457, Office Action dated Apr. 8, 2016.  
 U.S. Appl. No. 14/094,721, Office Action dated Nov. 17, 2016.  
 U.S. Appl. No. 14/223,893, Office Action dated Nov. 14, 2016.  
 U.S. Appl. No. 14/223,893, Office Action dated Nov. 7, 2016.  
 U.S. Appl. No. 14/052,381, Office Action dated Feb. 21, 2017.  
 U.S. Appl. No. 14/094,721, Office Action dated Mar. 17, 2107.  
 U.S. Appl. No. 14/223,893, Office Action dated Mar. 28, 2017.  
 U.S. Appl. No. 15/294,683, Office Action dated Feb. 10, 2017.  
 U.S. Appl. No. 14/052,381, Notice of Allowance dated Jun. 16, 2017.  
 U.S. Appl. No. 14/223,893, Notice of Allowance dated Aug. 11, 2017.  
 U.S. Appl. No. 14/846,986, Office Action dated Aug. 3, 2017.

\* cited by examiner






FIGURE 1






FIGURE 2









FIGURE 3








**FIGURE 5**



**FIGURE 6**








FIGURE 7




**FIGURE 8**



**FIGURE 9**



**FIGURE 10**




FIGURE 11






FIGURE 12




FIGURE 13






FIGURE 14




FIGURE 15









FIGURE 16

**FIGURE 17**



**FIGURE 18**

**FIGURE 19**






FIGURE 20

# METHOD AND APPARATUS FOR PROVIDING DATA PROCESSING AND CONTROL IN MEDICAL COMMUNICATION SYSTEM

## RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 13/356,598 filed Jan. 23, 2012, now U.S. Pat. No. 8,571,808, which is a continuation of U.S. patent application Ser. No. 12/152,623 filed May 14, 2008, now U.S. Pat. No. 8,103,471, entitled "Method And Apparatus For Providing Data Processing And Control In A Medical Communication System" which claims priority to U.S. provisional application no. 60/917,859 filed May 14, 2007, entitled "Method And Apparatus For Providing Data Processing And Control In A Medical Communication System", the disclosures of each of which are incorporated herein by reference for all purposes.

## BACKGROUND

Analyte, e.g., glucose monitoring systems including continuous and discrete monitoring systems generally include a small, lightweight battery powered and microprocessor controlled system which is configured to detect signals proportional to the corresponding measured glucose levels using an electrometer, and RF signals to transmit the collected data. One aspect of certain analyte monitoring systems include a transcutaneous or subcutaneous analyte sensor configuration which is, for example, partially mounted on the skin of a subject whose analyte level is to be monitored. The sensor cell may use a two or three-electrode (work, reference and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.

The analyte sensor may be configured so that a portion thereof is placed under the skin of the patient so as to detect the analyte levels of the patient, and another portion of segment of the analyte sensor that is in communication with the transmitter unit. The transmitter unit is configured to transmit the analyte levels detected by the sensor over a wireless communication link such as an RF (radio frequency) communication link to a receiver/monitor unit. The receiver/monitor unit performs data analysis, among others on the received analyte levels to generate information pertaining to the monitored analyte levels. To provide flexibility in analyte sensor manufacturing and/or design, among others, tolerance of a larger range of the analyte sensor sensitivities for processing by the transmitter unit is desirable.

In view of the foregoing, it would be desirable to have a method and system for providing data processing and control for use in medical telemetry systems such as, for example, analyte monitoring systems.

## SUMMARY

In one embodiment method and apparatus for receiving a signal associated with a monitored analyte level from an in vivo analyte sensor, retrieving a predetermined number of stored signals associated with the monitored analyte level, determining glucose trend information based on the received signal and the retrieved predetermined number of stored signals, and updating a prior trend information based on at least a portion of the retrieved predetermined number of prior analyte level signals, is disclosed.

These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.

## BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a block diagram of a data monitoring and management system for practicing one or more embodiments of the present disclosure;

FIG. 2 is a block diagram of the transmitter unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure;

FIG. 3 is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure;

FIGS. 4A-4B illustrate a perspective view and a cross sectional view, respectively of an analyte sensor in accordance with one embodiment of the present disclosure;

FIG. 5 is a flowchart illustrating ambient temperature compensation routine for determining on-skin temperature information in accordance with one embodiment of the present disclosure;

FIG. 6 is a flowchart illustrating digital anti-aliasing filtering routing in accordance with one embodiment of the present disclosure;

FIG. 7 is a flowchart illustrating actual or potential sensor insertion or removal detection routine in accordance with one embodiment of the present disclosure;

FIG. 8 is a flowchart illustrating receiver unit processing corresponding to the actual or potential sensor insertion or removal detection routine of FIG. 7 in accordance with one embodiment of the present disclosure;

FIG. 9 is a flowchart illustrating data processing corresponding to the actual or potential sensor insertion or removal detection routine in accordance with another embodiment of the present disclosure;

FIG. 10 is a flowchart illustrating a concurrent passive notification routine in the data receiver/monitor unit of the data monitoring and management system of FIG. 1 in accordance with one embodiment of the present disclosure;

FIG. 11 is a flowchart illustrating a data quality verification routine in accordance with one embodiment of the present disclosure;

FIG. 12 is a flowchart illustrating a rate variance filtering routine in accordance with one embodiment of the present disclosure;

FIG. 13 is a flowchart illustrating a composite sensor sensitivity determination routine in accordance with one embodiment of the present disclosure;

FIG. 14 is a flowchart illustrating an outlier data point verification routine in accordance with one embodiment of the present disclosure;

FIG. 15 is a flowchart illustrating a sensor stability verification routine in accordance with one embodiment of the present disclosure;

FIG. 16 illustrates analyte sensor code determination in accordance with one embodiment of the present disclosure;

FIG. 17 illustrates an early user notification function associated with the analyte sensor condition in one aspect of the present disclosure;

FIG. 18 illustrates uncertainty estimation associated with glucose level rate of change determination in one aspect of the present disclosure;

FIG. 19 illustrates glucose trend determination in accordance with one embodiment of the present disclosure; and



FIG. 20 illustrates glucose trend determination in accordance with another embodiment of the present disclosure.

#### DETAILED DESCRIPTION

As described in further detail below, in accordance with the various embodiments of the present disclosure, there is provided a method and apparatus for providing data processing and control for use in a medical telemetry system. In particular, within the scope of the present disclosure, there are provided method and system for providing data communication and control for use in a medical telemetry system such as, for example, a continuous glucose monitoring system.

FIG. 1 illustrates a data monitoring and management system such as, for example, analyte (e.g., glucose) monitoring system 100 in accordance with one embodiment of the present disclosure. The subject invention is further described primarily with respect to a glucose monitoring system for convenience and such description is in no way intended to limit the scope of the invention. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes, e.g., lactate, and the like.

Analytes that may be monitored include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored.

The analyte monitoring system 100 includes a sensor 101, a transmitter unit 102 coupled to the sensor 101, and a primary receiver unit 104 which is configured to communicate with the transmitter unit 102 via a communication link 103. The primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 for evaluating the data received by the primary receiver unit 104. Moreover, the data processing terminal in one embodiment may be configured to receive data directly from the transmitter unit 102 via a communication link which may optionally be configured for bi-directional communication.

Also shown in FIG. 1 is a secondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from the transmitter unit 102. Moreover, as shown in the Figure, the secondary receiver unit 106 is configured to communicate with the primary receiver unit 104 as well as the data processing terminal 105. Indeed, the secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105. As discussed in further detail below, in one embodiment of the present disclosure, the secondary receiver unit 106 may be configured to include a limited number of functions and features as compared with the primary receiver unit 104. As such, the secondary receiver unit 106 may be configured substantially in a smaller compact housing or embodied in a device such as a wrist watch, for example. Alternatively, the secondary receiver unit 106 may be configured with the same or substantially similar functionality as the primary receiver unit 104, and may be configured to be used in conjunction

with a docking cradle unit for placement by bedside, for night time monitoring, and/or bi-directional communication device.

Only one sensor 101, transmitter unit 102, communication link 103, and data processing terminal 105 are shown in the embodiment of the analyte monitoring system 100 illustrated in FIG. 1. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system 100 may include one or more sensor 101, transmitter unit 102, communication link 103, and data processing terminal 105. Moreover, within the scope of the present disclosure, the analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each device is configured to be uniquely identified by each of the other devices in the system so that communication conflict is readily resolved between the various components within the analyte monitoring system 100.

In one embodiment of the present disclosure, the sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor 101 may be configured to continuously sample the analyte level of the user and convert the sampled analyte level into a corresponding data signal for transmission by the transmitter unit 102. In one embodiment, the transmitter unit 102 is coupled to the sensor 101 so that both devices are positioned on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously under the skin layer of the user. The transmitter unit 102 performs data processing such as filtering and encoding on data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103.

In one embodiment, the analyte monitoring system 100 is configured as a one-way RF communication path from the transmitter unit 102 to the primary receiver unit 104. In such embodiment, the transmitter unit 102 transmits the sampled data signals received from the sensor 101 without acknowledgement from the primary receiver unit 104 that the transmitted sampled data signals have been received. For example, the transmitter unit 102 may be configured to transmit the encoded sampled data signals at a fixed rate (e.g., at one minute intervals) after the completion of the initial power on procedure. Likewise, the primary receiver unit 104 may be configured to detect such transmitted encoded sampled data signals at predetermined time intervals. Alternatively, the analyte monitoring system 100 may be configured with a bi-directional RF (or otherwise) communication between the transmitter unit 102 and the primary receiver unit 104.

Additionally, in one aspect, the primary receiver unit 104 may include two sections. The first section is an analog interface section that is configured to communicate with the transmitter unit 102 via the communication link 103. In one embodiment, the analog interface section may include an RF receiver and an antenna for receiving and amplifying the data signals from the transmitter unit 102, which are thereafter, demodulated with a local oscillator and filtered through a band-pass filter. The second section of the primary receiver unit 104 is a data processing section which is configured to process the data signals received from the transmitter unit 102 such as by performing data decoding, error detection and correction, data clock generation, and data bit recovery.

In operation, upon completing the power-on procedure, the primary receiver unit 104 is configured to detect the presence of the transmitter unit 102 within its range based



## 5

on, for example, the strength of the detected data signals received from the transmitter unit **102** or a predetermined transmitter identification information. Upon successful synchronization with the corresponding transmitter unit **102**, the primary receiver unit **104** is configured to begin receiving from the transmitter unit **102** data signals corresponding to the user's detected analyte level. More specifically, the primary receiver unit **104** in one embodiment is configured to perform synchronized time hopping with the corresponding synchronized transmitter unit **102** via the communication link **103** to obtain the user's detected analyte level.

Referring again to FIG. 1, the data processing terminal **105** may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs)), and the like, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal **105** may further be connected to a data network (not shown) for storing, retrieving and updating data corresponding to the detected analyte level of the user.

Within the scope of the present disclosure, the data processing terminal **105** may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the receiver unit **104** for receiving, among others, the measured analyte level. Alternatively, the receiver unit **104** may be configured to integrate an infusion device therein so that the receiver unit **104** is configured to administer insulin therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the transmitter unit **102**.

Additionally, the transmitter unit **102**, the primary receiver unit **104** and the data processing terminal **105** may each be configured for bi-directional wireless communication such that each of the transmitter unit **102**, the primary receiver unit **104** and the data processing terminal **105** may be configured to communicate (that is, transmit data to and receive data from) with each other via a wireless communication link. More specifically, the data processing terminal **105** may in one embodiment be configured to receive data directly from the transmitter unit **102** via a communication link, where the communication link, as described above, may be configured for bi-directional communication.

In this embodiment, the data processing terminal **105** which may include an insulin pump, may be configured to receive the analyte signals from the transmitter unit **102**, and thus, incorporate the functions of the receiver unit **104** including data processing for managing the patient's insulin therapy and analyte monitoring. In one embodiment, the communication link **103** may include one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, a Zigbee® transmission protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements) while avoiding potential data collision and interference.

FIG. 2 is a block diagram of the transmitter of the data monitoring and detection system shown in FIG. 1 in accordance with one embodiment of the present disclosure. Referring to the Figure, the transmitter unit **102** in one embodiment includes an analog interface **201** configured to communicate with the sensor **101** (FIG. 1), a user input **202**, and a temperature detection section **203**, each of which is

## 6

operatively coupled to a transmitter processor **204** such as a central processing unit (CPU).

Further shown in FIG. 2 are a transmitter serial communication section **205** and an RF transmitter **206**, each of which is also operatively coupled to the transmitter processor **204**. Moreover, a power supply **207** such as a battery is also provided in the transmitter unit **102** to provide the necessary power for the transmitter unit **102**. Additionally, as can be seen from the Figure, clock **208** is provided to, among others, supply real time information to the transmitter processor **204**.

As can be seen from FIG. 2, the sensor **101** (FIG. 1) is provided four contacts, three of which are electrodes—work electrode (W) **210**, guard contact (G) **211**, reference electrode (R) **212**, and counter electrode (C) **213**, each operatively coupled to the analog interface **201** of the transmitter unit **102**. In one embodiment, each of the work electrode (W) **210**, guard contact (G) **211**, reference electrode (R) **212**, and counter electrode (C) **213** may be made using a conductive material that is either printed or etched, for example, such as carbon which may be printed, or metal foil (e.g., gold) which may be etched, or alternatively provided on a substrate material using laser or photolithography.

In one embodiment, a unidirectional input path is established from the sensor **101** (FIG. 1) and/or manufacturing and testing equipment to the analog interface **201** of the transmitter unit **102**, while a unidirectional output is established from the output of the RF transmitter **206** of the transmitter unit **102** for transmission to the primary receiver unit **104**. In this manner, a data path is shown in FIG. 2 between the aforementioned unidirectional input and output via a dedicated link **209** from the analog interface **201** to serial communication section **205**, thereafter to the processor **204**, and then to the RF transmitter **206**. As such, in one embodiment, via the data path described above, the transmitter unit **102** is configured to transmit to the primary receiver unit **104** (FIG. 1), via the communication link **103** (FIG. 1), processed and encoded data signals received from the sensor **101** (FIG. 1). Additionally, the unidirectional communication data path between the analog interface **201** and the RF transmitter **206** discussed above allows for the configuration of the transmitter unit **102** for operation upon completion of the manufacturing process as well as for direct communication for diagnostic and testing purposes.

As discussed above, the transmitter processor **204** is configured to transmit control signals to the various sections of the transmitter unit **102** during the operation of the transmitter unit **102**. In one embodiment, the transmitter processor **204** also includes a memory (not shown) for storing data such as the identification information for the transmitter unit **102**, as well as the data signals received from the sensor **101**. The stored information may be retrieved and processed for transmission to the primary receiver unit **104** under the control of the transmitter processor **204**. Furthermore, the power supply **207** may include a commercially available battery.

The transmitter unit **102** is also configured such that the power supply section **207** is capable of providing power to the transmitter for a minimum of about three months of continuous operation after having been stored for about eighteen months in a low-power (non-operating) mode. In one embodiment, this may be achieved by the transmitter processor **204** operating in low power modes in the non-operating state, for example, drawing no more than approximately 1  $\mu$ A of current. Indeed, in one embodiment, the final step during the manufacturing process of the transmitter unit **102** may place the transmitter unit **102** in the lower power,



non-operating state (i.e., post-manufacture sleep mode). In this manner, the shelf life of the transmitter unit 102 may be significantly improved. Moreover, as shown in FIG. 2, while the power supply unit 207 is shown as coupled to the processor 204, and as such, the processor 204 is configured to provide control of the power supply unit 207, it should be noted that within the scope of the present disclosure, the power supply unit 207 is configured to provide the necessary power to each of the components of the transmitter unit 102 shown in FIG. 2.

Referring back to FIG. 2, the power supply section 207 of the transmitter unit 102 in one embodiment may include a rechargeable battery unit that may be recharged by a separate power supply recharging unit (for example, provided in the receiver unit 104) so that the transmitter unit 102 may be powered for a longer period of usage time. Moreover, in one embodiment, the transmitter unit 102 may be configured without a battery in the power supply section 207, in which case the transmitter unit 102 may be configured to receive power from an external power supply source (for example, a battery) as discussed in further detail below.

Referring yet again to FIG. 2, the temperature detection section 203 of the transmitter unit 102 is configured to monitor the temperature of the skin near the sensor insertion site. The temperature reading is used to adjust the analyte readings obtained from the analog interface 201. The RF transmitter 206 of the transmitter unit 102 may be configured for operation in the frequency band of 315 MHz to 322 MHz, for example, in the United States. Further, in one embodiment, the RF transmitter 206 is configured to modulate the carrier frequency by performing Frequency Shift Keying and Manchester encoding. In one embodiment, the data transmission rate is 19,200 symbols per second, with a minimum transmission range for communication with the primary receiver unit 104.

Referring yet again to FIG. 2, also shown is a leak detection circuit 214 coupled to the guard contact (G) 211 and the processor 204 in the transmitter unit 102 of the data monitoring and management system 100. The leak detection circuit 214 in accordance with one embodiment of the present disclosure may be configured to detect leakage current in the sensor 101 to determine whether the measured sensor data is corrupt or whether the measured data from the sensor 101 is accurate.

FIG. 3 is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure. Referring to FIG. 3, the primary receiver unit 104 includes a blood glucose test strip interface 301, an RF receiver 302, an input 303, a temperature detection section 304, and a clock 305, each of which is operatively coupled to a receiver processor 307. As can be further seen from the Figure, the primary receiver unit 104 also includes a power supply 306 operatively coupled to a power conversion and monitoring section 308. Further, the power conversion and monitoring section 308 is also coupled to the receiver processor 307. Moreover, also shown are a receiver serial communication section 309, and an output 310, each operatively coupled to the receiver processor 307.

In one embodiment, the test strip interface 301 includes a glucose level testing portion to receive a manual insertion of a glucose test strip, and thereby determine and display the glucose level of the test strip on the output 310 of the primary receiver unit 104. This manual testing of glucose can be used to calibrate sensor 101. The RF receiver 302 is configured to communicate, via the communication link 103 (FIG. 1) with the RF transmitter 206 of the transmitter unit

102, to receive encoded data signals from the transmitter unit 102 for, among others, signal mixing, demodulation, and other data processing. The input 303 of the primary receiver unit 104 is configured to allow the user to enter information into the primary receiver unit 104 as needed. In one aspect, the input 303 may include one or more keys of a keypad, a touch-sensitive screen, or a voice-activated input command unit. The temperature detection section 304 is configured to provide temperature information of the primary receiver unit 104 to the receiver processor 307, while the clock 305 provides, among others, real time information to the receiver processor 307.

Each of the various components of the primary receiver unit 104 shown in FIG. 3 is powered by the power supply 306 which, in one embodiment, includes a battery. Furthermore, the power conversion and monitoring section 308 is configured to monitor the power usage by the various components in the primary receiver unit 104 for effective power management and to alert the user, for example, in the event of power usage which renders the primary receiver unit 104 in sub-optimal operating conditions. An example of such sub-optimal operating condition may include, for example, operating the vibration output mode (as discussed below) for a period of time thus substantially draining the power supply 306 while the processor 307 (thus, the primary receiver unit 104) is turned on. Moreover, the power conversion and monitoring section 308 may additionally be configured to include a reverse polarity protection circuit such as a field effect transistor (FET) configured as a battery activated switch.

The serial communication section 309 in the primary receiver unit 104 is configured to provide a bi-directional communication path from the testing and/or manufacturing equipment for, among others, initialization, testing, and configuration of the primary receiver unit 104. Serial communication section 309 can also be used to upload data to a computer, such as time-stamped blood glucose data. The communication link with an external device (not shown) can be made, for example, by cable, infrared (IR) or RF link. The output 310 of the primary receiver unit 104 is configured to provide, among others, a graphical user interface (GUI) such as a liquid crystal display (LCD) for displaying information. Additionally, the output 310 may also include an integrated speaker for outputting audible signals as well as to provide vibration output as commonly found in handheld electronic devices, such as mobile telephones presently available. In a further embodiment, the primary receiver unit 104 also includes an electro-luminescent lamp configured to provide backlighting to the output 310 for output visual display in dark ambient surroundings.

Referring back to FIG. 3, the primary receiver unit 104 in one embodiment may also include a storage section such as a programmable, non-volatile memory device as part of the processor 307, or provided separately in the primary receiver unit 104, operatively coupled to the processor 307. The processor 307 is further configured to perform Manchester decoding as well as error detection and correction upon the encoded data signals received from the transmitter unit 102 via the communication link 103.

In a further embodiment, the one or more of the transmitter unit 102, the primary receiver unit 104, secondary receiver unit 106, or the data processing terminal/infusion section 105 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a glucose meter. In still a further embodiment, the user or patient manipulating or using the analyte monitoring system 100 (FIG. 1) may manually input the blood glucose



value using, for example, a user interface (for example, a keyboard, keypad, and the like) incorporated in the one or more of the transmitter unit **102**, the primary receiver unit **104**, secondary receiver unit **106**, or the data processing terminal/infusion section **105**.

Additional detailed description of the continuous analyte monitoring system, its various components including the functional descriptions of the transmitter are provided in U.S. Pat. No. 6,175,752 issued Jan. 16, 2001 entitled "Analyte Monitoring Device and Methods of Use", and in application Ser. No. 10/745,878 filed Dec. 26, 2003 entitled "Continuous Glucose Monitoring System and Methods of Use", each assigned to the Assignee of the present application, and each of which are incorporated herein by reference for all purposes.

FIGS. 4A-4B illustrate a perspective view and a cross sectional view, respectively of an analyte sensor in accordance with one embodiment of the present disclosure. Referring to FIG. 4A, a perspective view of a sensor **400**, the major portion of which is above the surface of the skin **410**, with an insertion tip **430** penetrating through the skin and into the subcutaneous space **420** in contact with the user's biofluid such as interstitial fluid. Contact portions of a working electrode **401**, a reference electrode **402**, and a counter electrode **403** can be seen on the portion of the sensor **400** situated above the skin surface **410**. Working electrode **401**, a reference electrode **402**, and a counter electrode **403** can be seen at the end of the insertion tip **430**.

Referring now to FIG. 4B, a cross sectional view of the sensor **400** in one embodiment is shown. In particular, it can be seen that the various electrodes of the sensor **400** as well as the substrate and the dielectric layers are provided in a stacked or layered configuration or construction. For example, as shown in FIG. 4B, in one aspect, the sensor **400** (such as the sensor **101** FIG. 1), includes a substrate layer **404**, and a first conducting layer **401** such as a carbon trace disposed on at least a portion of the substrate layer **404**, and which may comprise the working electrode. Also shown disposed on at least a portion of the first conducting layer **401** is a sensing layer **408**.

Referring back to FIG. 4B, a first insulation layer such as a first dielectric layer **405** is disposed or stacked on at least a portion of the first conducting layer **401**, and further, a second conducting layer **409** such as another carbon trace may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer) **405**. As shown in FIG. 4B, the second conducting layer **409** may comprise the reference electrode **402**, and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl).

Referring still again to FIG. 4B, a second insulation layer **406** such as a dielectric layer in one embodiment may be disposed or stacked on at least a portion of the second conducting layer **409**. Further, a third conducting layer **403** which may include carbon trace and that may comprise the counter electrode **403** may in one embodiment be disposed on at least a portion of the second insulation layer **406**. Finally, a third insulation layer **407** is disposed or stacked on at least a portion of the third conducting layer **403**. In this manner, the sensor **400** may be configured in a stacked or layered construction or configuration such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer).

Additionally, within the scope of the present disclosure, some or all of the electrodes **401**, **402**, **403** may be provided on the same side of the substrate **404** in a stacked construction as described above, or alternatively, may be provided in a co-planar manner such that each electrode is disposed on

the same plane on the substrate **404**, however, with a dielectric material or insulation material disposed between the conducting layers/electrodes. Furthermore, in still another aspect of the present disclosure, the one or more conducting layers such as the electrodes **401**, **402**, **403** may be disposed on opposing sides of the substrate **404**.

Referring back to the Figures, in one embodiment, the transmitter unit **102** (FIG. 1) is configured to detect the current signal from the sensor **101** (FIG. 1) and the skin temperature near the sensor **101**, which are preprocessed by, for example, the transmitter processor **204** (FIG. 2) and transmitted to the receiver unit (for example, the primary receiver unit **104** (FIG. 1) periodically at a predetermined time interval, such as for example, but not limited to, once per minute, once every two minutes, once every five minutes, or once every ten minutes. Additionally, the transmitter unit **102** may be configured to perform sensor insertion detection and data quality analysis, information pertaining to which are also transmitted to the receiver unit **104** periodically at the predetermined time interval. In turn, the receiver unit **104** may be configured to perform, for example, skin temperature compensation as well as calibration of the sensor data received from the transmitter unit **102**.

For example, in one aspect, the transmitter unit **102** may be configured to oversample the sensor signal at a nominal rate of four samples per second, which allows the analyte anti-aliasing filter in the transmitter unit **102** to attenuate noise (for example, due to effects resulting from motion or movement of the sensor after placement) at frequencies above 2 Hz. More specifically, in one embodiment, the transmitter processor **204** may be configured to include a digital filter to reduce aliasing noise when decimating the four Hz sampled sensor data to once per minute samples for transmission to the receiver unit **104**. As discussed in further detail below, in one aspect, a two stage Kaiser FIR filter may be used to perform the digital filtering for anti-aliasing. While Kaiser FIR filter may be used for digital filtering of the sensor signals, within the scope of the present disclosure, other suitable filters may be used to filter the sensor signals.

In one aspect, the temperature measurement section **203** of the transmitter unit **102** may be configured to measure once per minute the on skin temperature near the analyte sensor at the end of the minute sampling cycle of the sensor signal. Within the scope of the present disclosure, different sample rates may be used which may include, for example, but not limited to, measuring the on skin temperature for each 30 second periods, each two minute periods, and the like. Additionally, as discussed above, the transmitter unit **102** may be configured to detect sensor insertion, sensor signal settling after sensor insertion, and sensor removal, in addition to detecting for sensor—transmitter system failure modes and sensor signal data integrity. Again, this information is transmitted periodically by the transmitter unit **102** to the receiver unit **104** along with the sampled sensor signals at the predetermined time intervals.

Referring again to the Figures, as the analyte sensor measurements are affected by the temperature of the tissue around the transcutaneously positioned sensor **101**, in one aspect, compensation of the temperature variations and effects on the sensor signals are provided for determining the corresponding glucose value. Moreover, the ambient temperature around the sensor **101** may affect the accuracy of the on skin temperature measurement and ultimately the glucose value determined from the sensor signals. Accordingly, in one aspect, a second temperature sensor is provided in the transmitter unit **102** away from the on skin temperature sensor (for example, physically away from the tempera-



## 11

ture measurement section **203** of the transmitter unit **102**), so as to provide compensation or correction of the on skin temperature measurements due to the ambient temperature effects. In this manner, the accuracy of the estimated glucose value corresponding to the sensor signals may be attained.

In one aspect, the processor **204** of the transmitter unit **102** may be configured to include the second temperature sensor, and which is located closer to the ambient thermal source within the transmitter unit **102**. In other embodiments, the second temperature sensor may be located at a different location within the transmitter unit **102** housing where the ambient temperature within the housing of the transmitter unit **102** may be accurately determined.

Referring now to FIG. 5, in one aspect, an ambient temperature compensation routine for determining the on-skin temperature level for use in the glucose estimation determination based on the signals received from the sensor **101**. Referring to FIG. 5, for each sampled signal from the sensor **101**, a corresponding measured temperature information is received (**510**), for example, by the processor **204** from the temperature measurement section **203** (which may include, for example, a thermistor provided in the transmitter unit **102**). In addition, a second temperature measurement is obtained (**520**), for example, including a determination of the ambient temperature level using a second temperature sensor provided within the housing the transmitter unit **102**.

In one aspect, based on a predetermined ratio of thermal resistances between the temperature measurement section **203** and the second temperature sensor (located, for example, within the processor **204** of the transmitter unit **102**), and between the temperature measurement section **203** and the skin layer on which the transmitter unit **102** is placed and coupled to the sensor **101**, ambient temperature compensation may be performed (**530**), to determine the corresponding ambient temperature compensated on skin temperature level (**540**). In one embodiment, the predetermined ratio of the thermal resistances may be approximately 0.2. However, within the scope of the present disclosure, this thermal resistance ratio may vary according to the design of the system, for example, based on the size of the transmitter unit **102** housing, the location of the second temperature sensor within the housing of the transmitter unit **102**, and the like.

With the ambient temperature compensated on-skin temperature information, the corresponding glucose value from the sampled analyte sensor signal may be determined.

Referring again to FIG. 2, the processor **204** of the transmitter unit **102** may include a digital anti-aliasing filter. Using analog anti-aliasing filters for a one minute measurement data sample rate would require a large capacitor in the transmitter unit **102** design, and which in turn impacts the size of the transmitter unit **102**. As such, in one aspect, the sensor signals may be oversampled (for example, at a rate of 4 times per second), and then the data is digitally decimated to derive a one-minute sample rate.

As discussed above, in one aspect, the digital anti-aliasing filter may be used to remove, for example, signal artifacts or otherwise undesirable aliasing effects on the sampled digital signals received from the analog interface **201** of the transmitter unit **102**. For example, in one aspect, the digital anti-aliasing filter may be used to accommodate decimation of the sensor data from approximately four Hz samples to one-minute samples. In one aspect, a two stage FIR filter may be used for the digital anti-aliasing filter, and which includes improved response time, pass band and stop band properties.

## 12

Referring to FIG. 6, a routine for digital anti-aliasing filtering is shown in accordance with one embodiment. As shown, in one embodiment, at each predetermined time period such as every minute, the analog signal from the analog interface **201** corresponding to the monitored analyte level received from the sensor **101** (FIG. 1) is sampled (**610**). For example, at every minute, in one embodiment, the signal from the analog interface **201** is over-sampled at approximately 4 Hz. Thereafter, the first stage digital filtering on the over-sampled data is performed (**620**), where, for example, a  $\frac{1}{4}$  down-sampling from 246 samples to 41 samples is performed, and the resulting 41 samples is further down-sampled at the second stage digital filtering (**630**) such that, for example, a  $\frac{1}{41}$  down-sampling is performed from 41 samples (from the first stage digital filtering), to a single sample. Thereafter, the filter is reset (**640**), and the routine returns to the beginning for the next minute signal received from the analog interface **201**.

While the use of FIR filter, and in particular the use of Kaiser FIR filter, is within the scope of the present disclosure, other suitable filters, such as FIR filters with different weighting schemes or IIR filters, may be used.

Referring yet again to the Figures, the transmitter unit **102** may be configured in one embodiment to periodically perform data quality checks including error condition verifications and potential error condition detections, and also to transmit the relevant information related to one or more data quality, error condition or potential error condition detection to the receiver unit **104** with the transmission of the monitored sensor data. For example, in one aspect, a state machine may be used in conjunction with the transmitter unit **102** and which may be configured to be updated four times per second, the results of which are transmitted to the receiver unit **104** every minute.

In particular, using the state machine, the transmitter unit **102** may be configured to detect one or more states that may indicate when a sensor is inserted, when a sensor is removed from the user, and further, may additionally be configured to perform related data quality checks so as to determine when a new sensor has been inserted or transcutaneously positioned under the skin layer of the user and has settled in the inserted state such that the data transmitted from the transmitter unit **102** does not compromise the integrity of signal processing performed by the receiver unit **104** due to, for example, signal transients resulting from the sensor insertion.

That is, when the transmitter unit **102** detects low or no signal from the sensor **101**, which is followed by detected signals from the sensor **101** that is above a given signal, the processor **204** may be configured to identify such transition is monitored signal levels and associate with a potential sensor insertion state. Alternatively, the transmitter unit **102** may be configured to detect the signal level above another predetermined threshold level, which is followed by the detection of the signal level from the sensor **101** that falls below the predetermined threshold level. In such a case, the processor **204** may be configured to associate or identify such transition or condition in the monitored signal levels as a potential sensor removal state.

Accordingly, when either of potential sensor insertion state or potential sensor removal state is detected by the transmitter unit **102**, this information is transmitted to the receiver unit **104**, and in turn, the receiver unit may be configured to prompt the user for confirmation of either of the detected potential sensor related state. In another aspect, the sensor insertion state or potential sensor removal state may be detected or determined by the receiver unit based on



## 13

one or more signals received from the transmitter unit **102**. For example, similar to an alarm condition or a notification to the user, the receiver unit **104** may be configured to display a request or a prompt on the display or an output unit of the receiver unit **104** a text and/or other suitable notification message to inform the user to confirm the state of the sensor **101**.

For example, the receiver unit **104** may be configured to display the following message: "New Sensor Inserted?" or a similar notification in the case where the receiver unit **104** receives one or more signals from the transmitter unit **102** associated with the detection of the signal level below the predetermined threshold level for the predefined period of time, followed by the detection of the signal level from the sensor **101** above another predetermined threshold level for another predefined period of time. Additionally, the receiver unit **104** may be configured to display the following message: "Sensor Removed?" or a similar notification in the case where the receiver unit **104** received one or more signals from the transmitter unit **102** associated with the detection of the signal level from the sensor **101** that is above another predetermined threshold level for another predefined period of time, which is followed by the detection of the signal level from the sensor **101** that falls below the predetermined threshold level for the predefined period of time.

Based on the user confirmation received, the receiver unit **104** may be further configured to execute or perform additional related processing and routines in response to the user confirmation or acknowledgement. For example, when the user confirms, using the user interface input/output mechanism of the receiver unit **104**, for example, that a new sensor has been inserted, the receiver unit **104** may be configured to initiate a new sensor insertion related routines including, such as, for example, sensor calibration routine including, for example, calibration timer, sensor expiration timer and the like. Alternatively, when the user confirms or it is determined that the sensor **101** is not properly positioned or otherwise removed from the insertion site, the receiver unit **104** may be accordingly configured to perform related functions such as, for example, stop displaying of the glucose values/levels, or deactivating the alarm monitoring conditions.

On the other hand, in response to the potential sensor insertion notification generated by the receiver unit **104**, if the user confirms that no new sensor has been inserted, then the receiver unit **104** in one embodiment is configured to assume that the sensor **101** is in acceptable operational state, and continues to receive and process signals from the transmitter unit **102**.

In this manner, in cases, for example, when there is momentary movement or temporary dislodging of the sensor **101** from the initially positioned transcutaneous state, or when one or more of the contact points between sensor **101** and the transmitter unit **102** are temporarily disconnected, but otherwise, the sensor **101** is operational and within its useful life, the routine above provides an option to the user to maintain the usage of the sensor **101** without replacing the sensor **101** prior to the expiration of its useful life. In this manner, in one aspect, false positive indications of sensor **101** failure may be identified and addressed.

For example, FIG. 7 is a flowchart illustrating actual or potential sensor insertion or removal detection routine in accordance with one embodiment of the present disclosure. Referring to the Figure, the current analyte related signal is first compared to a predetermined signal characteristic (**710**). In one aspect, the predetermined signal characteristic

## 14

may include one of a signal level transition from below a first predetermined level (for example, but not limited to 18 ADC (analog to digital converter) counts) to above the first predetermined level, a signal level transition from above a second predetermined level (for example, but not limited to 9 ADC counts) to below the second predetermined level, a transition from below a predetermined signal rate of change threshold to above the predetermined signal rate of change threshold, and a transition from above the predetermined signal rate of change threshold to below the predetermined signal rate of change threshold.

In this manner, in one aspect of the present disclosure, based on a transition state of the received analyte related signals, it may be possible to determine the state of the analyte sensor **720**, and based on which, the user or the patient may confirm whether the analyte sensor is in the desired or proper position, has been temporarily dislocated, or otherwise, removed from the desired insertion site so as to require a new analyte sensor.

In this manner, in one aspect, when the monitored signal from the sensor **101** crosses a transition level (**730**) (for example, from no or low signal level to a high signal level, or vice versa), the transmitter unit **102** may be configured to generate an appropriate output data associated with the sensor signal transition (**740**), for transmission to the receiver unit **104** (FIG. 1). Additionally, as discussed in further detail below, in another embodiment, the determination of whether the sensor **101** has crossed a transition level may be determined by the receiver/monitor unit **104/106** based, at least in part on the one or more signals received from the transmitter unit **102**.

FIG. 8 is a flowchart illustrating receiver unit processing corresponding to the actual or potential sensor insertion or removal detection routine of FIG. 7 in accordance with one embodiment of the present disclosure. Referring now to FIG. 8, when the receiver unit **104** receives the generated output data from the transmitter unit **102** (**810**), a corresponding operation state is associated with the received output data (**820**), for example, related to the operational state of the sensor **101**. Moreover, a notification associated with the sensor operation state is generated and output to the user on the display unit or any other suitable output segment of the receiver unit **104** (**830**). When a user input signal is received in response to the notification associated with the sensor state operation state (**840**), the receiver unit **104** is configured to execute one or more routines associated with the received user input signal (**850**).

That is, as discussed above, in one aspect, if the user confirms that the sensor **101** has been removed, the receiver unit **104** may be configured to terminate or deactivate alarm monitoring and glucose displaying functions. On the other hand, if the user confirms that a new sensor **101** has been positioned or inserted into the user, then the receiver unit **104** may be configured to initiate or execute routines associated with the new sensor insertion, such as, for example, calibration procedures, establishing calibration timer, and establishing sensor expiration timer.

In a further embodiment, based on the detected or monitored signal transition, the receiver/monitor unit may be configured to determine the corresponding sensor state without relying upon the user input or confirmation signal associated with whether the sensor is dislocated or removed from the insertion site, or otherwise, operating properly.

FIG. 9 is a flowchart illustrating data processing corresponding to the actual or potential sensor insertion or removal detection routine in accordance with another embodiment of the present disclosure. Referring to FIG. 9,



## 15

a current analyte related signal is received and compared to a predetermined signal characteristic (910). Thereafter, an operational state associated with an analyte monitoring device such as, for example, the sensor 101 (FIG. 1) is retrieved (920) from a storage unit or otherwise resident in, for example, a memory of the receiver/monitor unit. Additionally, a prior analyte related signal is also retrieved from the storage unit, and compared to the current analyte related signal received (930). An output data is generated which is associated with the operational state (940), and which at least in part is based on the one or more of the received current analyte related signal and the retrieved prior analyte related signal.

Referring again to FIG. 9, when the output data is generated, a corresponding user input command or signal is received in response to the generated output data (950), and which may include one or more of a confirmation, verification, or rejection of the operational state related to the analyte monitoring device.

FIG. 10 is a flowchart illustrating a concurrent passive notification routine in the data receiver/monitor unit of the data monitoring and management system of FIG. 1 in accordance with one embodiment of the present disclosure. Referring to FIG. 10, a predetermined routine is executed for a predetermined time period to completion (1010). During the execution of the predetermined routine, an alarm condition is detected (1020), and when the alarm or alert condition is detected, a first indication associated with the detected alarm or alert condition is output concurrent to the execution of the predetermined routine (1030).

That is, in one embodiment, when a predefined routine is being executed, and an alarm or alert condition is detected, a notification is provided to the user or patient associated with the detected alarm or alert condition, but which does not interrupt or otherwise disrupt the execution of the predefined routine. Referring back to FIG. 10, upon termination of the predetermined routine, another output or second indication associated with the detected alarm condition is output or displayed (1040).

More specifically, in one aspect, the user interface notification feature associated with the detected alarm condition is output to the user only upon the completion of an ongoing routine which was in the process of being executed when the alarm condition is detected. As discussed above, when such alarm condition is detected during the execution of a predetermined routine, a temporary alarm notification such as, for example, a backlight indicator, a text output on the user interface display or any other suitable output indication may be provided to alert the user or the patient of the detected alarm condition substantially in real time, but which does not disrupt an ongoing routine.

Within the scope of the present disclosure, the ongoing routine or the predetermined routine being executed may include one or more of performing a finger stick blood glucose test (for example, for purposes of periodically calibrating the sensor 101), or any other processes that interface with the user interface, for example, on the receiver/monitor unit 104/106 (FIG. 1) including, but not limited to the configuration of device settings, review of historical data such as glucose data, alarms, events, entries in the data log, visual displays of data including graphs, lists, and plots, data communication management including RF communication administration, data transfer to the data processing terminal 105 (FIG. 1), or viewing one or more alarm conditions with a different priority in a preprogrammed or determined alarm or notification hierarchy structure.

## 16

In this manner, in one aspect of the present disclosure, the detection of one or more alarm conditions may be presented or notified to the user or the patient, without interrupting or disrupting an ongoing routine or process in, for example, the receiver/monitor unit 104/106 of the data monitoring and management system 100 (FIG. 1).

Referring now back to the Figures, FIG. 11 is a flowchart illustrating a data quality verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. 11, initially the data quality status flags are cleared or initialized or reset (1110). Thereafter data quality checks or verifications are performed, for example, as described above (1120). Thereafter, data quality flag is generated and associated with the data packet when data quality check has failed (1130). In one aspect, the generated data quality flag may be based on data quality verification such that when the underlying condition being verified is determined to be acceptable, the data quality flag may return a value of zero (or one or more predetermined value). Alternatively, in the case where the underlying condition being verified is determined to be not within the acceptable criteria (or above the acceptable level), the associated data quality flag may return a value of one (or one or more predetermined value associated with the determination of such condition).

Referring to FIG. 11, the data packet including the raw glucose data as well as the data quality flags are transmitted, for example, to the receiver/monitor unit 104/106 for further processing (1140). As described above, the data quality checks may be performed in the transmitter unit 102 (FIG. 1) and/or in the receiver/monitor unit 104/106 in the data monitoring and management system 100 (FIG. 1) in one aspect of the present disclosure.

FIG. 12 is a flowchart illustrating a rate variance filtering routine in accordance with one embodiment of the present disclosure. Referring to FIG. 12, when glucose related data is detected or received (1210), for example, for each predetermined time intervals such as every minute, every five minutes or any other suitable time intervals, a plurality of filtered values based on the received or detected glucose related data is determined (1220). For example, as discussed above, in one aspect, using, for example, an FIR filter, or based on a weighted average, a plurality of filtered values for a 15 minute and two minute glucose related data including the currently received or detected glucose related are determined.

Referring back to FIG. 12, weighting associated with the plurality of filtered values is determined (1230). Thereafter, a rate of change of the glucose level based in part on the detected or received glucose related data is determined as well as a standard deviation of the rate of change based on the glucose related data (1240). Further, a weighted average associated with the current detected or monitored glucose related data is determined based on the plurality of filtered values and the determined standard deviation of the rate of change and/or the rate of change of the glucose level (1250). For example, when the rate of change is determined to be high relative to the rate of change variation, the filtered value based on the two minute data is weighted more heavily. On the other hand, when the rate of change is determined to be low relative to the rate of change variation, the filtered glucose related data includes the one of the plurality of filtered values based on the 15 minute data which is weighted more heavily. In this manner, in one aspect, there is provided a rate variance filtering approach which may be configured to dynamically modify the weighting function or data filtering to, for example, reduce undesirable variation in glucose related signals due to factors such as noise.



17

FIG. 13 is a flowchart illustrating a composite sensor sensitivity determination routine in accordance with one embodiment of the present disclosure. Referring to FIG. 13, during scheduled calibration time periods or otherwise manual calibration routines to calibrate the analyte sensor, when a current blood glucose value is received or detected (1310), a current or present sensitivity is determined based on the detected blood glucose value (1320). For example, the current sensitivity may be determined by taking a ratio of the current glucose sensor value and the detected blood glucose value.

Referring to FIG. 13, a prior sensitivity previously determined is retrieved, for example, from the storage unit (1330). In one aspect, the prior sensitivity may include a previous sensitivity determined during a prior sensor calibration event, or may be based on the nominal sensor sensitivity based on the sensor code from manufacturing, for example. Returning again to FIG. 13, a first weighted parameter is applied to the current sensitivity, and a second weighted parameter is applied to the retrieved prior sensitivity (1340). For example, based on the time lapsed between the calibration event associated with the retrieved prior sensitivity value and the current calibration event (associated with the current or received blood glucose value), the first and second weighted parameters may be modified (e.g., increased or decreased in value) to improve accuracy.

Referring back to FIG. 13, based on applying the first and the second weighted parameters to the current sensitivity and the retrieved prior sensitivity, a composite sensitivity associated with the analyte sensor for the current calibration event is determined (1350). For example, using a time based approach, in one embodiment, the sensitivity associated with the analyte sensor for calibration may be determined to, for example, reduce calibration errors or accommodate sensitivity drift.

FIG. 14 is a flowchart illustrating an outlier data point verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. 14, and as discussed in detail above, in determining composite sensitivity associated with the analyte sensor calibration, in one aspect, an outlier data point may be detected and accordingly corrected. For example, in one aspect, two successive sensitivities associated with two successive calibration events for the analyte sensor is compared (1410). If it is determined that the comparison between the two sensitivities are within a predetermined range (1420), the composite sensitivity for the current calibration of the analyte sensor is determined based on the two successive sensitivity values (1430), using, for example, the weighted approach described above.

Referring back to FIG. 14, if it is determined that the comparison of the two successive sensitivities results in the compared value being outside of the predetermined range, then the user may be prompted to enter or provide a new current blood glucose value (for example, using a blood glucose meter) (1440). Based on the new blood glucose value received, an updated or new sensitivity associated with the analyte sensor is determined (1450). Thereafter, the new or updated sensitivity determined is compared with the two prior sensitivities compared (at 1420) to determine whether the new or updated sensitivity is within a predefined range of either of the two prior sensitivities (1460). If it is determined that the new or updated sensitivity of the analyte sensor is within the predefined range of either of the two prior successive sensitivities, a composite sensitivity is determined based on the new or updated sensitivity and the one of the two prior successive sensitivities within the

18

defined range of which the new or updated sensitivity is determined (1470). On the other hand, if it is determined that the new or updated sensitivity is not within the predefined range of either of the two prior sensitivities, then the routine repeats and prompts the user to enter a new blood glucose value (1440).

FIG. 15 is a flowchart illustrating a sensor stability verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. 15, and as discussed above, between predetermined or scheduled baseline calibration events to calibrate the sensor, the analyte sensor sensitivity stability may be verified, to determine, for example, if additional stability calibrations may be needed prior to the subsequent scheduled baseline calibration event.

For example, referring to FIG. 15, in one embodiment, after the second baseline calibration event to calibrate the analyte sensor, the user may be prompted to provide a new blood glucose value. With the current blood glucose value received (1510), the current sensor sensitivity is determined (1520). Thereafter, the most recent stored sensor sensitivity value from prior calibration event is retrieved (for example, from a storage unit) (1530), and the determined current sensor sensitivity is compared with the retrieved stored sensor sensitivity value to determine whether the difference, if any, between the two sensitivity values are within a predefined range (1540).

Referring back to FIG. 15, if it is determined that the difference between the current and retrieved sensitivity values are within the predefined range, then the stability associated with the sensor sensitivity is confirmed (1550), and no additional calibration is required prior to the subsequent scheduled baseline calibration event. On the other hand, if it is determined that the difference between the current sensitivity and the retrieved prior sensitivity is not within the predefined range, then after a predetermined time period has lapsed (1560), the routine returns to the beginning and prompts the user to enter a new blood glucose value to perform the stability verification routine.

In this manner, in one aspect, the stability checks may be performed after the outlier check is performed, and a new composite sensitivity determined as described above. Accordingly, in one aspect, analyte sensor sensitivity may be monitored as the sensitivity attenuation is dissipating to, among others, improve accuracy of the monitored glucose data and sensor stability.

FIG. 16 illustrates analyte sensor code determination in accordance with one embodiment. Referring to the Figure, a batch of predetermined number of analyte sensors, for example, glucose sensors is selected during manufacturing process (1610). The batch of predetermined number of glucose sensors may be a set number, or a variable number depending upon other manufacturing or post-manufacturing parameters (for example, such as testing, quality control verification, or packaging).

Referring to FIG. 16, the sensitivity of each selected glucose sensor is determined (1620). For example, in one aspect, in vitro sensitivity determination is performed for each selected glucose sensor to determine the corresponding sensitivity. Thereafter, a variation between the determined sensitivity of each glucose sensor is determined (1630). That is, in one aspect, the determined in vitro sensitivity associated with each selected glucose sensor is compared to a predefined variation tolerance level (1640).

In one aspect, if the variation of the sensitivity is greater than the predefined variation tolerance level for one of the selected glucose sensor in the selected batch of predetermined number of glucose sensors (1660), then the entire



batch or lot may be rejected and not used. In another aspect, the rejection of the selected batch of predetermined number of glucose sensors may be based on a predetermined number of sensors within the selected batch that are associated with a sensitivity value that exceeds the predefined variation tolerance level. For example, in a batch of 30 glucose sensors, if 10 percent (or 3 sensors) has sensitivity that exceeds the predefined variation tolerance level, then the entire batch of 30 glucose sensors is rejected and not further processed during the manufacturing routine, for example, for use. Within the scope of the present disclosure, the number of sensors in the selected batch, or the number of sensors within the selected batch that exceeds the predefined variation tolerance level to result in a failed batch may be varied depending upon, for example, but not limited to, sensor manufacturing process, sensor testing routines, quality control verification, or other parameters associated with sensor performance integrity.

Referring back to FIG. 16, if it is determined that the sensitivity of the selected glucose sensors are within the predefined variation tolerance level, a nominal sensitivity is determined for the batch of the predetermined number of glucose sensors (1650). Further, a sensor code is associated with the determined nominal sensitivity for the batch of predetermined number of analyte sensors (1670).

In one aspect, the sensor code may be provided on the labeling for the batch of glucose sensors for use by the patient or the user. For example, in one aspect, the analyte monitoring system may prompt the user to enter the sensor code into the system (for example, to the receiver unit 104/106 FIG. 1) after the sensor has been initially positioned in the patient and prior to the first sensor calibration event. In a further aspect, based on the sensor code, the analyte monitoring system may be configured to retrieve the nominal sensitivity associated with the batch of predetermined number of sensors for, for example, calibration of the transcutaneously positioned glucose sensor.

FIG. 17 illustrates an early user notification function associated with the analyte sensor condition in one aspect of the present disclosure. Referring to FIG. 17, upon detection of the sensor insertion (1710), for example, in fluid contact with the patient or user's analyte (e.g., interstitial fluid), one or more adverse data condition occurrence associated with the patient or the user's analyte level is monitored (1720). Examples of the adverse data condition occurrence may include, for example, a persistent low sensor signal (for example, continuous for a predefined time period), identified data quality flags or identifiers associated with erroneous or potentially inaccurate sensor signal level or sensor condition (for example, dislodged or improperly positioned sensor).

Referring to FIG. 17, when it is determined that the monitored adverse data condition occurrence exceeds a predetermined number of occurrences during a predefined time period (1730), a notification is generated and provided to the user to either replace the sensor, or to perform one or more verifications to confirm, for example, but not limited to, that the sensor is properly inserted and positioned, the transmitter unit is in proper contact with the sensor (1740).

On the other hand, if the number of adverse data condition occurrence has not occurred during the predefined time period, in one aspect, the routine continues to monitor for the occurrence of such condition during the set time period. In one aspect, the predetermined time period during which the occurrence of adverse data condition occurrence may be approximately one hour from the initial sensor positioning. Alternatively, this time period may be shorter or longer, depending upon the particular system configuration.

In this manner, in the event that adverse condition related to the sensor is determined and persists for a given time period from the initial sensor insertion, the user or the patient is notified to either replace the sensor or to perform one or more troubleshooting steps to make sure that the components of the analyte monitoring system are functioning properly. Indeed, in one aspect, when an adverse condition related to the sensor is identified early on, the user is not inconvenienced by continuing to maintain the sensor in position even though the sensor may be defective or improperly positioned, or is associated with one or more other adverse conditions that will not allow the sensor to function properly.

FIG. 18 illustrates uncertainty estimation associated with glucose level rate of change determination in one aspect of the present disclosure. Referring to FIG. 18, based on the monitored glucose level from the glucose sensor, a rate of change estimate of the glucose level fluctuation is determined (1810). Further, an estimation of an uncertainty range or level associated with the determined rate of change of the glucose level is determined (1820). That is, in one aspect, a predefined rate of uncertainty determination may be performed, such as for example, a rate of change variance calculation. If the uncertainty determination is within a predetermined threshold level (1830), then an output is generated and/or provided to the user (1840).

For example, when it is determined that the determined uncertainty measure is within the threshold level, the analyte monitoring system may be configured to display or output an indication to the user or the patient, such as a glucose level trend indicator (for example, a visual trend arrow or a distinctive audible alert (increasing or decreasing tone, etc)). On the other hand, if it is determined that the uncertainty measure related to the rate of change estimate exceeds the predetermined threshold, the determined rate of change of glucose level may be rejected or discarded (or stored but not output to the user or the patient). In one aspect, the uncertainty measure may include a predefined tolerance parameter associated with the accuracy of the determined rate of change of the monitored glucose level.

In one aspect, the uncertainty measure or the tolerance level related to the rate of change of monitored glucose level may include, but not limited to, corrupt or erroneous data associated with the monitored glucose level, unacceptably large number of missing data associated with the monitored glucose level, rate of acceleration or deceleration of the monitored glucose level that exceeds a defined or acceptable threshold level, or any other parameters that may contribute to potential inaccuracy in the determined rate of change of the monitored glucose level.

Accordingly, in one aspect, the accuracy of the analyte monitoring system may be maintained by, for example, disabling the output function associated with the rate of change determination related to the monitored glucose level, so that the user or the patient does not take corrective actions based on potentially inaccurate information. That is, as discussed above, in the event when it is determined that the determined uncertainty measure or parameter exceeds an acceptable tolerance range, the output function on the receiver unit 104/106 in the analyte monitoring system 100 may be disabled temporarily, or until the uncertainty measure of parameter related to the rate of change of the glucose level being monitored is within the acceptable tolerance range.

When the monitored rate of change of the glucose level is steady (or within a defined range) and medically significant with respect to the monitored glucose measurement, a pre-



diction of future or anticipated glucose level may be considered reliable based on the determined rate of change level. However, the monitored glucose level time series is such that the determined rate of change estimate may be less certain.

Accordingly, in one aspect, the present disclosure accounts for the rate of change estimates having varying degrees of certainty. Since clinical treatment decisions may be made based on these estimates, it is important to discount, or not display or output to the user, the determined rate of change estimates with a high degree of uncertainty.

In one aspect, the rate of change value and its uncertainty determine a probability distribution. This distribution may be assumed to be Gaussian, for example. Within the scope of the present disclosure, the uncertainty measure may be calculated in various ways. In one embodiment, it may include a standard deviation determination. Another possibility is to use the coefficient of variation (CV), which is the standard deviation of the rate of change divided by the rate of change. A combination of these uncertainty measures may also be used.

In one aspect, various ranges of rates of change may be combined into bins. For example, bin edges at  $\pm 2$  mg/dL and at  $\pm 1$  mg/dL may be defined in one embodiment resulting in five bins. Each bin may be represented by a position of a trend arrow indicator, associated with the monitored glucose level. When the rate of change is included in one of the determined bins, the associated trend arrow position may be displayed.

Further, the presence of uncertainty may modify the trend arrow position that is displayed to the user or the patient. In one aspect, a determination that involves the uncertainty measure results in a metric value which may be a simple comparison of the uncertainty value to a predefined threshold. There are also other possible metrics. Another approach may use a different predefined threshold value for each bin.

In one aspect, an unacceptable metric value may cause no trend arrow indicator to be displayed. Alternatively, this condition may be indicated by a change in the characteristics of the display to the user or the patient. For example, the trend arrow indicator may flash, change color, change shape, change size, change length or change width, among others. A further embodiment may include the trend arrow indicator showing no significant rate-of-change. Within the scope of the present disclosure, other user output configurations including audible and/or vibratory output are contemplated.

In one aspect, the uncertainty measure may be characterized a number of ways. One is the standard deviation of the monitored glucose levels over the period in which the rate of change is estimated. Another is the coefficient of variation (CV), which, as discussed above, is the standard deviation of the monitored glucose trend divided by the rate of change value. A further characterization may include a probabilistic likelihood estimate. Yet a further characterization is the output of a statistical filter or estimator such as a Kalman filter. The uncertainty comparison may be based on one of these techniques or a combination of two or more of these techniques. Also, different uncertainty characteristics may be used for different rate-of-change results. For instance, in one embodiment, a CV formulation may be used for high glucose values and a standard deviation formulation may be used for low glucose values.

FIG. 19 illustrates glucose trend determination in accordance with one embodiment of the present disclosure. Referring to FIG. 19, a current value associated with a monitored glucose level is received (1910). One or more prior values associated with the monitored glucose level (previously

stored, for example) is retrieved (1920). With the current and prior values associated with the monitored glucose level, a most recent calibration scale factor is applied to the current and prior values associated with the monitored glucose level (1930). After applying the calibration scale factor to the current and prior values, the trend associated with the monitored glucose level is determined (1940).

In this manner, in one aspect, with the updated calibration of the glucose sensor including a newly determined sensitivity, buffered or stored values associated with the monitored glucose level may be updated using, for example, the updated calibration information, resulting, for example, in revised or modified prior values associated with the monitored glucose level. As such, in one embodiment, stored or buffered values associated with the monitored glucose level may be updated and, the updated values may be used to determine glucose trend information or rate of change of glucose level calculation. In this manner, accuracy of the glucose trend information may be improved by applying the most recent calibration parameters to previously detected and stored values associated with the monitored glucose level, when, for example, the previously detected and stored values are used for further analysis, such as, glucose trend determination or rate of change of glucose level calculation.

FIG. 20 illustrates glucose trend determination in accordance with another embodiment of the present disclosure. Referring to FIG. 20, a current value associated with a monitored glucose level is received (2010). One or more prior values associated with the monitored glucose level (previously stored, for example) is retrieved (2020). With the current and prior values associated with the monitored glucose level, a rate of change estimate of the monitored glucose level is determined (2030). Referring back to FIG. 20, an uncertainty parameter associated with the rate of change estimate is determined (2040).

In one aspect, an uncertainty parameter may be predetermined and programmed into the analyte monitoring system 100 (for example, in the receiver unit 104/106). Alternatively, the uncertainty parameter may be dynamically configured to vary depending upon the number of data available for determination of the glucose level rate of change determination, or upon other programmable parameters that may include user specified uncertainty parameters. Within the scope of the present disclosure, the uncertainty parameter may include the number of acceptable missing or unavailable values when performing the monitored glucose level rate of change estimation. Referring back to FIG. 20, when it is determined that the uncertainty parameter is within an acceptable predetermined tolerance range, the rate of change of the monitored glucose level is determined and output to the user or the patient (2050).

In one embodiment, the uncertainty parameter may be associated with the time spacing of the current and prior values, such that when the rate of change estimation requires a preset number of values, and no more than a predetermined number of values (optionally consecutively, or non consecutively) are unavailable, the rate of change estimation is performed. In this manner, for example, when a large number of values associated with the monitored glucose level (for example, 5 consecutive one minute data—tolerance range) are unavailable, corrupt or otherwise unusable for purposes of rate of change determination, the uncertainty parameter is deemed to exceed the predetermined tolerance range, and the rate of change calculation may not be performed, or may be postponed.

As discussed, the rate of change in glucose for a patient or a user may be used by glucose monitoring devices to



direct glucose trend indicators for display to the patient or the user such that the patient or the user may base treatment decisions not only on the current glucose levels but also on the current direction or change in the glucose level. The rate of change estimate may also be used to project into the future if a predetermined glucose threshold (upper or lower range or limit) is not exceeded within a specific time period based on the current glucose level and rate of change information. Within the scope of the present disclosure, other projection approaches may be based on higher order derivatives of the rate of change, and/or other statistical likelihood formulations that can be contemplated for prediction of a future event.

One approach to determine the rate of change is to calculate the difference between two glucose samples and dividing the result by the time difference between the samples. Another approach may be to fit a time series of glucose readings to a function, such as a polynomial, using techniques such as the least squares techniques. The number of samples and the time period of the samples may impact the accuracy of the rate of change estimate in the form of a trade off between noise reduction properties and lag introduced.

Referring again to the Figures, in one aspect, the transmitter unit **102** may be configured to perform one or more periodic or routine data quality checks or verification before transmitting the data packet to the receiver/monitor unit **104/106**. For example, in one aspect, for each data transmission (e.g., every 60 seconds, or some other predetermined transmission time interval), the transmitter data quality flags in the data packet are reset, and then it is determined whether any data field in the transmission data packet includes an error flag. If one error flag is detected, then in one aspect, the entire data packet may be considered corrupt, and this determination is transmitted to the receiver/monitor unit **104/106**. Alternatively, the determination that the entire data packet is corrupt may be performed by the receiver/monitor unit **104/106**. Accordingly, in one aspect, when at least one data quality check fails in the transmitter data packet, the entire packet is deemed to be in error, and the associated monitored analyte level is discarded, and not further processed by the receiver/monitor unit **104/106**.

In another aspect, the data quality check in the transmitter unit **102** data packet may be performed so as to identify each error flag in the data packet, and those identified error flag are transmitted to the receiver/monitor unit **104/106** in addition to the associated monitored analyte level information. In this manner, in one aspect, if the error flag is detected in the transmitter data packet which is not relevant to the accuracy of the data associated with the monitored analyte level, the error indication is flagged and transmitted to the receiver/monitor unit **104/106** in addition to the data indicating the monitored analyte level.

In one aspect, examples of error condition that may be detected or flagged in the transmitter unit **102** data packet include sensor connection fault verification by, for example, determining, among others, whether the counter electrode voltage signal is within a predetermined range, resolution of the data associated with the monitored analyte level, transmitter unit temperature (ambient and/or on-skin temperature) out of range, and the like. As discussed above, the data quality check in the transmitter unit **102** may be performed serially, such that detection of an error condition or an error flag renders the entire data packet invalid or deemed corrupt. In this case, such data is reported as including error to the receiver/monitor unit **104/106**, but not used to process the associated monitored analyte level. In another aspect, all

data quality fields in the data packet of the transmitter unit **102** may be checked for error flags, and if there are error flags detected, the indication of the detected error flags is transmitted with the data packet to the receiver/monitor unit **104/106** for further processing.

In one embodiment, on the receiver/monitor unit **104/106** side, for each periodic data packet received (for example every 60 seconds or some other predetermined time interval), the receiver/monitor unit **104/106** may be configured to receive the raw glucose data including any data quality check flags from the transmitter unit **102**, and to apply temperature compensation and/or calibration to the raw data to determine the corresponding glucose data (with any data quality flags as may have been identified). The unfiltered, temperature compensated and/or calibrated glucose data is stored along with any data quality flags in a FIFO buffer (including, for example, any invalid data identifier). Alternatively, a further data quality check may be performed on the temperature compensated and calibrated glucose data to determine the rate of change or variance of the measured glucose data. For example, in one embodiment, a high variance check or verification is performed on 30 minutes of glucose data stored in the FIFO buffer. If it is determined that the rate of variance exceeds a predetermined threshold, then the data packet in process may be deemed invalid. On the other hand, if the rate of variance does not exceed the predetermined threshold, the results including the glucose data and any associated validity or error flags are stored in the FIFO buffer.

Thereafter, the data processing is performed on the stored data to determine, for example, the respective glucose level estimation or calculation. That is, the stored data in the FIFO buffer in one embodiment is filtered to reduce unwanted variation in signal measurements due to noise or time delay, among others. In one aspect, when the rate of change or variance of glucose data stored in the FIFO buffer, for example, is within a predetermined limit, the glucose measurements are filtered over a 15 minute period. On the other hand, if it is determined that the rate of change is greater than the predetermined limit, a more responsive 2 minute filtering is performed. In one aspect, the filtering is performed for each 60 second glucose data. In this manner, in one embodiment, a rate variance filter is provided that may be configured to smooth out the variation in the glucose measurement when the glucose level is relatively stable, and further, that can respond quickly when the glucose level is changing rapidly. The rate variance filter may be implemented in firmware as an FIR filter which is stable and easy to implement in integer-based firmware, for example, implemented in fixed point math processor.

In one embodiment, for each 60 second glucose data received, two filtered values and two additional parameters are determined. That is, using an FIR filter, for example, a weighted average for a 15 minute filtered average glucose value and a 2 minute average filtered glucose value are determined. In addition, a rate of change based on 15 minutes of data as well as a standard deviation associated with the rate estimate is determined. To determine the final filtered glucose value for output and/or display to the user, a weighted average of the two determined filtered glucose values is determined, where when the rate of change of the glucose values is high, then weighting is configured to tend towards the 2 minute filtered value, while when the rate of change of the glucose value is low the weighting tends towards the 15 minute filtered value. In this manner, when the rate of change is high, the 2 minute filtered value is weighted more heavily (as the 15 minute filtered average



25

value potentially introduces lag, which at higher rates of change, likely results in large error).

Referring back, during the calibration routine, in one embodiment, when the discrete blood glucose value is received for purposes of calibration of the glucose data from the sensor **101** (FIG. **1**), the processing unit of the receiver/monitor unit **104/106** is configured to retrieve from the FIFO buffer two of the last five valid transmitter data packets that do not include any data quality flags associated with the respective data packets. In this manner, in one aspect, calibration validation check may be performed when the blood glucose value is provided to the receiver/monitor unit **104/106** determined using, for example, a blood glucose meter. In the event that two valid data packets from the last five data packets cannot be determined, the receiver/monitor unit **104/106** is configured to alarm or notify the user, and the calibration routine is terminated.

On the other hand, if the calibration validation check is successful, the sensitivity associated with the sensor **101** (FIG. **1**) is determined, and its range verified. In one aspect, if the sensitivity range check fails, again, the receiver/monitor unit **104/106** may be configured to alarm or otherwise notify the user and terminate the calibration routine. Otherwise, the determined sensitivity is used for subsequent glucose data measurement and processing (until a subsequent calibration is performed).

Referring back to the Figures, in one aspect, determination of optimal sensitivity evaluates one or more potential error sources or conditions present in blood glucose value for calibration and the potential sensitivity drift. Accordingly, using a weighted average of the current sensitivity determined for calibration and previously determined sensitivity, the sensitivity accuracy may be optimized. For example, in one embodiment, a weighted average of the two most recent sensitivities determined used for calibration may be used to determine a composite sensitivity determination to improve accuracy and reduce calibration errors. In this aspect, earlier blood glucose values used for calibration are discarded to accommodate for sensitivity drift. In one embodiment, the number of blood glucose values used for determining the weighted average, and also, the weighting itself may be varied using one or more approaches including, for example, a time based technique.

For example, for each sensor calibration routine, the sensitivity derived from the current blood glucose value from the current blood glucose test and the stored sensitivity value associated with the most recent prior stored blood glucose value may be used to determine a weighted average value that is optimized for accuracy. Within the scope of the present disclosure, as discussed above, the weighting routine may be time based such that if the earlier stored blood glucose value used for prior calibration is greater than a predetermined number of hours, then the weighting value assigned to the earlier stored blood glucose may be less heavy, and a more significant weighting value may be given to the current blood glucose value to determine the composite sensitivity value.

In one embodiment, a lookup table may be provided for determining the composite sensitivity determination based on a variable weighting average which provides a non-linear correction to reduce errors and improve accuracy of the sensor sensitivity.

The determined composite sensitivity in one embodiment may be used to convert the sensor ADC counts to the corresponding calibrated glucose value. In one aspect, the composite sensitivity determined may be used to minimize outlier calibrations and unstable sensitivity during, for

26

example, the initial use periods. That is, during the data validation routines, outlier check may be performed to determine whether the sensitivity associated with each successive calibration is within a predetermined threshold or range.

For example, the sensor **101** (FIG. **1**) may require a predetermined number of baseline calibrations during its use. For a five day operational lifetime of a sensor, four calibrations may be required at different times during the five day period. Moreover, during this time period, additional stability related calibrations may be required if the sensor sensitivity is determined to be unstable after the second baseline calibration performed, for example, at the 12<sup>th</sup> hour (or other suitable time frame) of the sensor usage after the initial calibration within the first 10 hours of sensor deployment.

In one aspect, during the outlier check routine, it is determined whether the sensitivity variance between two successive calibrations is within a predetermined acceptable range. If it is determined that the variance is within the predetermined range, then the outlier check is confirmed, and a new composite sensitivity value is determined based on a weighted average of the two sensitivity values. As discussed above, the weighted average may include a time based function or any other suitable discrete weighting parameters.

If on the other hand, the variance between the two sensitivities is determined to be outside of the predetermined acceptable range, then the second (more recent) sensitivity value is considered to be an outlier (for example, due to ESA, change in sensitivity or due to bad or erroneous blood glucose value), and the user is prompted to perform another fingerstick testing to enter a new blood glucose value (for example, using a blood glucose meter). If the second current sensitivity associated with the new blood glucose value is determined to be within the predetermined acceptable range from the prior sensitivity, then the earlier current sensitivity value is discarded, and the composite sensitivity is determined based on applying a weighting function or parameter on the prior sensitivity value, and the second current sensitivity value (discarding the first current sensitivity value which is outside the predetermined acceptable range and considered to be an outlier).

On the other hand, when the second current sensitivity value is determined to be within the predetermined acceptable range of the first current sensitivity value, but not within the predetermined acceptable range of the prior sensitivity value (of the two successive calibrations described above), then it is determined in one embodiment that a sensitivity shift, rather than an outlier, has occurred or is detected from the first current sensitivity value to the second current sensitivity value. Accordingly, the composite sensitivity may be determined based, in this case, on the first and second current sensitivity values (and discarding the prior sensitivity).

If, for example, the second current sensitivity value is determined to be outside the predetermined range of both of the two successive sensitivities described above, then the user in one embodiment is prompted to perform yet another blood glucose test to input another current blood glucose value, and the routine described above is repeated.

Furthermore, in accordance with another aspect, the determination of the sensitivity variance between two successive calibrations are within a predetermined acceptable range may be performed prior to the outlier check routine.

Referring to the Figures, during the period of use, as discussed above, the sensor **101** (FIG. **1**) is periodically



calibrated at predetermined time intervals. In one aspect, after the second baseline calibration (for example, at 12<sup>th</sup> hour of sensor **101** transcutaneously positioned in fluid contact with the user's analyte), sensor sensitivity stability verifications may be performed to determine whether, for example, additional stability calibrations may be necessary before the third baseline calibration is due. In one aspect, the sensitivity stability verification may be performed after the outlier checks as described above is performed, and a new composite sensitivity is determined, and prior to the third scheduled baseline calibration at the 24<sup>th</sup> hour (or at another suitable scheduled time period).

That is, the sensor sensitivity may be attenuated (e.g., ESA) early in the life of the positioned sensor **101** (FIG. 1), and if not sufficiently dissipated by the time of the first baseline calibration, for example, at the 10<sup>th</sup> hour (or later), and even by the time of the second calibration at the 12<sup>th</sup> hour. As such, in one aspect, a relative difference between the two sensitivities associated with the two calibrations is determined. If the determined relative difference is within a predefined threshold or range (for example, approximately 26% variation), then it is determined that the sufficient stability point has reached. On the other hand, if the relative difference determined is beyond the predefined threshold, then the user is prompted to perform additional calibrations at a timed interval (for example, at each subsequent 2 hour period) to determine the relative difference in the sensitivity and compared to the predefined range. This may be repeated for each two hour interval, for example, until acceptable stability point has been reached, or alternatively, until the time period for the third baseline calibration is reached, for example, at the 24<sup>th</sup> hour of sensor **101** (FIG. 1) use.

In this manner, in one aspect, the stability verification may be monitored as the sensitivity attenuation is dissipating over a given time period. While the description above is provided with particular time periods for baseline calibrations and additional calibration prompts for stability checks, for example, within the scope of the present disclosure, other time periods or calibration schedule including stability verifications may be used. In addition, other suitable predefined threshold or range of the relative sensitivity difference to determine acceptable attenuation dissipation other than approximately 26% may be used. Moreover, as discussed above, the predetermined calibration schedule for each sensor **101** (FIG. 1) may be modified from the example provided above, based on, for example, the system design and/or sensor **101** (FIG. 1) configuration.

Additionally, in one aspect, the user may be prompted to perform the various scheduled calibrations based on the calibration schedule provided. In the case where the scheduled calibration is not performed, in one embodiment, the glucose value determination for user display or output (on the receiver/monitor unit **104/106**, for example) based on the received sensor data may be disabled after a predetermined time period has lapsed. Further, the glucose value determination may be configured to resume when the prompted calibration is successfully completed.

In a further aspect, the scheduled calibration timing may be relative to the prior calibration time periods, starting with the initial sensor positioning. That is, after the initial transcutaneous positioning of the sensor **101** (FIG. 1) and the scheduled time period has elapsed to allow the sensor **101** to reach a certain stability point, the user may be prompted to perform the first baseline calibration as described above (for example, at the 10<sup>th</sup> hour since the initial sensor placement). Thereafter, in the case when the user waits until the 11<sup>th</sup> hour to perform the initial baseline calibration, the second sched-

uled calibration at the 12<sup>th</sup> hour, for example, may be performed at the 13<sup>th</sup> hour, so that the two hour spacing between the two calibrations are maintained, and the second calibration timing is based on the timing of the first successful baseline calibration performed. In an alternate embodiment, each scheduled calibration time period may be based on the timing of the initial sensor positioning. That is, rather than determining the appropriate subsequent calibration time periods based on the prior calibration performed, the timing of the scheduled calibration time periods may be made to be absolute and based from the time of the initial sensor placement.

Furthermore, in one aspect, when the scheduled calibration is not performed at the scheduled time periods, the glucose values may nevertheless be determined based on the sensor data for display to the user for a limited time period (for example, for no more than two hours from when the scheduled calibration time period is reached). In this manner, a calibration time window may be established or provided to the user with flexibility in performing the scheduled calibration and during which the glucose values are determined for output display to the user, for example. In one aspect, if within the calibration time window, the scheduled calibrations are not performed, the glucose values may be deemed in error, and thus not provided to the user or determined until the calibration is performed.

For example, after the initial successful baseline calibration at the 10<sup>th</sup> hour, for example, or at any other suitable scheduled initial baseline calibration time, glucose values are displayed or output to the user and stored in a memory. Thereafter, at the next scheduled calibration time period (for example, at the 12<sup>th</sup> hour), the user may be prompted to perform the second calibration. If the user does not perform the second calibration, a grace period of two hours, for example, is provided during which valid glucose values are provided to the user (for example, on the display unit of the receiver/monitor unit **104/106**) based on the prior calibration parameters (for example, the initial baseline calibration performed at the 10<sup>th</sup> hour). However, if the second calibration is still not performed after the grace period, in one aspect, no additional glucose values are provided to user, and until the scheduled calibration is performed.

In still another aspect, the user may supplement the scheduled calibrations, and perform manual calibration based on the information that the user has received. For example, in the case that the user determines that the calibration performed and determined to be successful by the receiver/monitor unit **104/106**, for example, is not sufficiently accurate, rather than replacing the sensor, the user may recalibrate the sensor even if the scheduled calibration time has not been reached. For example, based on a blood glucose test result, if the determined blood glucose level is not close to or within an acceptable range as compared to the sensor data, the user may determine that additional calibration may be needed.

Indeed, as the sensitivity value of a given sensor tends to stabilize over time, a manual user forced calibration later in the sensor's life may provide improved accuracy in the determined glucose values, as compared to the values based on calibrations performed in accordance with the prescribed or predetermined calibration schedule. Accordingly, in one aspect, additional manual calibrations may be performed in addition to the calibrations based on the predetermined calibration schedule.

In a further aspect, user notification functions may be programmed in the receiver/monitor unit **104/106**, or in the transmitter unit **102** (FIG. 1) to notify the user of initial



conditions associated with the sensor **101** (FIG. **1**) performance or integrity. That is, alarms or alerts, visual, auditory, and/or vibratory may be configured to be triggered when conditions related to the performance of the sensor is detected. For example, during the initial one hour period (or some other suitable time period) from the sensor insertion, in the case where data quality flags/conditions (described above) are detected, or in the case where low or no signal from the sensor is detected from a given period of time, an associated alarm or notification may be initiated or triggered to notify the user to verify the sensor position, the sensor contacts with the transmitter unit **102** (FIG. **1**), or alternatively, to replace the sensor with a new sensor. In this manner, rather than waiting a longer period until the acceptable sensor stability point has been reached, the user may be provided at an early stage during the sensor usage that the positioned sensor may be defective or has failed.

In addition, other detected conditions related to the performance of the sensor, calibration, detected errors associated with the glucose value determination may be provided to the user using one or more alarm or alert features. For example, when the scheduled calibration has been timely performed, and the grace period as described above has expired, in one embodiment, the glucose value is not processed for display or output to the user anymore. In this case, an alarm or alert notifying the user that the glucose value cannot be calculated is provided so that the user may timely take corrective actions such as performing the scheduled calibration. In addition, when other parameters that are monitored such as the temperature, sensor data, and other variables that are used to determine the glucose value, include error or otherwise is deemed to be corrupt, the user may be notified that the associated glucose value cannot be determined, so that the user may take corrective actions such as, for example, replacing the sensor, verifying the contacts between the sensor and the transmitter unit, and the like.

In this manner, in one embodiment, there is provided an alarm or notification function that detects or monitors one or more conditions associated with the glucose value determination, and notifies the user of the same when such condition is detected. Since the alarms or notifications associated with the glucose levels (such as, for example, alarms associated with potential hyperglycemic, hypoglycemic, or programmed trend or rate of change glucose level conditions) will be inactive if the underlying glucose values cannot be determined, by providing a timely notification or alarm to the user that the glucose value cannot be determined, the user can determine or be prompted/notified that these alarms associated with glucose levels are inactive.

In one aspect of the present disclosure, glucose trend information may be determined and provided to the user, for example, on the receiver/monitor unit **104/106**. For example, trend information in one aspect is based on the prior monitored glucose levels. When calibration is performed, the scaling used to determine the glucose levels may change. If the scaling for the prior glucose data (for example, one minute prior) is not changed, then in one aspect, the trend determination may be deemed more error prone. Accordingly, in one aspect, to determine accurate and improved trend determination, the glucose level determination is performed retrospectively for a 15 minute time interval based on the current glucose data when each successive glucose level is determined.

That is, in one aspect, with each minute determination of the real time glucose level, to determine the associated glucose trend information, the stored past 15 minute data associated with the determined glucose level is retrieved,

including the current glucose level. In this manner, the buffered prior glucose levels may be updated with new calibration to improve accuracy of the glucose trend information.

In one aspect, the glucose trend information is determined based on the past 15 minutes (or some other predetermined time interval) of glucose data including, for example, the current calibration parameter such as current sensitivity. Thereafter, when the next glucose data is received (at the next minute or based on some other timed interval), a new sensitivity is determined based on the new data point associated with the new glucose data. Also, the trend information may be determined based on the new glucose data and the past 14 minutes of glucose data (to total 15 minutes of glucose data). It is to be noted that while the trend information is determined based on 15 minutes of data as described above, within the scope of the present disclosure, other time intervals may be used to determine the trend information, including, for example, 30 minutes of glucose data, 10 minutes of glucose data, 20 minutes of glucose data, or any other appropriate time intervals to attain an accurate estimation of the glucose trend information.

In this manner, in one aspect of the present disclosure, the trend information for the historical glucose information may be updated based on each new glucose data received, retrospectively, based on the new or current glucose level information, and the prior 14 glucose data points (or other suitable number of past glucose level information). In another aspect, the trend information may be updated based on a select number of recent glucose level information such that, it is updated periodically based on a predetermined number of determined glucose level information for display or output to the user.

In still another aspect, in wireless communication systems such as the data monitoring and management system **100** (FIG. **10**), the devices or components intended for wireless communication may periodically be out of communication range. For example, the receiver/monitor unit **104/106** may be placed out of the RF communication range of the transmitter unit **102** (FIG. **1**). In such cases, the transmitted data packet from the transmitter unit **102** may not be received by the receiver/monitor unit **104/106**, or due to the weak signaling between the devices, the received data may be invalid or corrupt. In such cases, while there may be missing data points associated with the periodically monitored glucose levels, the trend information may be nevertheless determined, as the trend information is determined based on a predetermined number of past or prior glucose data points (for example, the past 15 minutes of glucose data).

That is, in one aspect, even if there a certain number of glucose data points within the 15 minute time frame that may be either not received by the receiver/monitor unit **104/106**, or alternatively be corrupt or otherwise invalid due to, for example, weakness in the communication link, the trend information may be determined. For example, given the 15 minutes of glucose data, if three or less non consecutive data points are not received or otherwise corrupt, the receiver/monitor unit **104/106** may determine the glucose trend information based on the prior 12 glucose data points that are received and considered to be accurate. As such, the features or aspects of the analyte monitoring system which are associated with the determined trend information may continue to function or operate as programmed.

That is, the projected alarms or alerts programmed into the receiver/monitor unit **104/106**, or any other alarm conditions associated with the detection of impending hyperglycemia, impending hypoglycemia, hyperglycemic condi-



tion or hypoglycemic condition (or any other alarm or notification conditions) may continue to operate as programmed even when there are a predetermined number or less of glucose data points. However, if and when the number of missing glucose data points exceed the tolerance threshold so as to accurately estimate or determine, for example, the glucose trend information, or any other associated alarm conditions, the display or output of the associated glucose trend information or the alarm conditions may be disabled.

For example, in one aspect, the glucose trend information and the rate of change of the glucose level (which is used to determine the trend information) may be based on 15 minute data (or data based on any other suitable time period) of the monitored glucose levels, where a predetermined number of missing data points within the 15 minutes may be tolerated. Moreover, using least squares approach, the rate of change of the monitored glucose level may be determined to estimate the trend, where the monitored glucose data is not evenly spaced in time. In this approach, the least squares approach may provide an uncertainty measure of the rate of change of the monitored glucose level. The uncertainty measure, in turn, may be partially dependent upon the number of data points available.

Indeed, using the approaches described above, the trend information or the rate of change of the glucose level may be estimated or determined without the need to determine which data point or glucose level is tolerable, and which data point is not tolerable. For example, in one embodiment, the glucose data for each minute including the missing data is retrieved for a predetermined time period (for example, 15 minute time period). Thereafter, least squares technique is applied to the 15 minute data points. Based on the least squares (or any other appropriate) technique, the uncertainty or a probability of potential variance or error of the rate of glucose level change is determined. For example, the rate of change may be determined to be approximately 1.5 mg/dL/minute  $\pm$  0.1 mg/dL/minute. In such a case, the 0.1mg/dL/minute may represent the uncertainty information discussed above, and may be higher or lower depending upon the number of data points in the 15 minutes of data that are missing or corrupt.

In this manner, in one aspect, the glucose trend information and/or the rate of change of monitored glucose level may be determined based on a predefined number of past monitored glucose level data points, even when a subset of the predefined number of past monitored glucose level data points are missing or otherwise determined to be corrupt. On the other hand, when the number of past glucose level data points based on which the glucose trend information is determined, exceeds the tolerance or acceptance level, for example, the display or output of the glucose trend information may be disabled. Additionally, in a further aspect, if it is determined that the underlying data points associated with the monitored glucose level based on which the trend information is determined, includes uncertainty or error factor that exceeds the tolerance level (for example, when there are more than a predetermined number of data points which deviate from a predefined level), the receiver/monitor unit **104/106**, for example, may be configured to disable or disallow the display or output of the glucose trend information.

For example, when the 15 minute glucose data including the current glucose level as well as the past 14 minutes of glucose level data is to be displayed or output to the user, and the determined rate variance of the 15 data points exceeds a preset threshold level (for example, 3.0), the glucose trend

information display function may be disabled. In one aspect, the variance may be determined based on the square function of the standard deviation of the 15 data points. In one aspect, this approach may be performed substantially on a real time basis for each minute glucose data. Accordingly, as discussed above, the glucose trend information may be output or displayed substantially in real time, and based on each new glucose data point received from the sensor/transmitter unit.

Additionally, when it is determined that the 15 data points (or any other suitable number of data points for determining glucose trend information, for example), deviate beyond a predetermined tolerance range, in one aspect, the 15 minute data may be deemed error prone or inaccurate. In this case, rather than outputting or displaying glucose trend information that may be erroneous, the receiver/monitor unit **104/106** may be configured to display the output or display function related to the output or display of the determined glucose trend information. The same may apply to the output or display of projected alarms whose estimates may be based in part, on the determined trend information. Accordingly, in one aspect, there may be instances when the projected alarm feature may be temporarily disabled where the underlying monitored glucose data points are considered to include more than acceptable levels of uncertainty or error.

In a further aspect, it is desired to determine an estimate of sensor sensitivity, and/or a range of acceptable or reasonable sensitivity. For example, during determination or verification of the glucose rate of change prior to calibration, the estimated sensor sensitivity information is necessary, for example, to determine whether the rate of change is within or below an acceptable threshold level, and/or further, within a desired range. Moreover, when determining whether the sensor sensitivity is within an acceptable or reasonable level, it may be necessary to ascertain a range of reasonable or acceptable sensitivity—for example, a verification range for the sensitivity value for a given sensor or batch of sensors.

Accordingly, in one aspect, during sensor manufacturing process, a predetermined number of sensor samples (for example, 16 samples) may be evaluated from each manufacturing lot of sensors (which may include, for example, approximately 500 sensors) and the nominal sensitivity for each lot (based, for example, on a mean calculation) may be determined. For example, during the manufacturing process, the predetermined number of sensors (for example, the 16 sensors) is sampled, and the sensitivity of each sampled sensor is measured in vitro. Thereafter, a mean sensitivity may be determined as an average value of the 16 sampled sensor's measured sensitivity, and thereafter, the corresponding sensor code is determined where the determined mean sensitivity falls within the preassigned sensitivity range. Based on the determined sensor code, the sensor packaging is labeled with the sensor code.

For example, each sensor code value (e.g., **105**, **106**, **107** or any suitable predetermined number or code) may be preassigned a sensitivity range (For example, code **105**: S1-S2, code **106**: S2-S3, and code **107**: S3-S4), where each sensitivity range (e.g., S1-S2, or S2-S3, or S3-S4) is approximately over a 10 percent increment (for example, S1 is approximately 90% of S2). Also, each sensor code (e.g., **105**, **106**, **107** etc) is assigned a nominal sensitivity value ( $S_n$ ) that is within the respective preassigned sensitivity range.

Referring back, when the user inserts the sensor or positions the sensor transcutaneously in place, the receiver/monitor unit **104/106** in one embodiment prompts the user to enter the associated sensor code. When the user enters the



33

sensor code (as derived from the sensor packing label discussed above), the receiver/monitor unit **104/106** is configured to retrieve or look up the nominal sensitivity associated with the user input sensor code (and the nominal sensitivity which falls within the preassigned sensitivity range associated with that sensor code, as described above). Thereafter, the receiver/monitor unit **104/106** may be configured to use the sensor code in performing associated routines such as glucose rate of change verification, data quality checks discussed above, and/or sensor sensitivity range acceptability or confirmation.

In a further aspect, the sensor codes may be associated with a coefficient of variation of the predetermined number of sampled sensors discussed above in addition to using the mean value determined as discussed above. In one embodiment, the coefficient of variation may be determined from the predetermined number of sampled sensors during the manufacturing process. In addition, the mean response time of the sampled sensors may be used by separately measuring the predetermined number of sampled sensors which may be used for lag correction adjustments and the like.

In this manner, in one aspect, the manufacturing process control described above ensures that the coefficient of variation of the sampled sensors is within a threshold value. That is, the value of the nominal sensitivity is used to determine a sensor code, selected or looked up from a predetermined table, and that is assigned to the sensors from the respective sensor lot in manufacturing. The user then enters the sensor code into the receiver/monitor unit that uses the sensor code to determine the glucose rate of change for purposes of data quality checking, for example, and also to determine validity or reasonableness of the sensitivity that is determined.

In one embodiment a method of determining glucose trend information may comprise, receiving a signal associated with a monitored analyte level from an in vivo analyte sensor, retrieving a predetermined number of stored signals associated with the monitored analyte level, determining glucose trend information based on the received signal and the retrieved predetermined number of stored signals, and updating a prior trend information based on at least a portion of the retrieved predetermined number of prior analyte level signals.

The trend information may be determined based on an analyte sensor sensitivity.

Updating the prior trend information may be based on the analyte sensor sensitivity.

Updating the prior trend information may include determining an updated analyte level of at least a portion of the retrieved predetermined number of prior analyte levels based on the current analyte sensor sensitivity.

One aspect may include displaying the updated prior trend information.

One aspect may include modifying a current display of the trend information based on the updated prior trend information.

Each of the predetermined number of prior analyte level signals and the current analyte level signal may be temporally separated by approximately one minute or less.

In one embodiment, an apparatus may comprise a communication unit to receive an analyte level signal from an in vivo analyte sensor, and a data processing unit coupled to the communication unit, the data processing unit configured to retrieve a predetermined number of stored analyte level signals, determine a trend information based on the current analyte level signal and the retrieved predetermined number of prior analyte level signals, and update a prior trend

34

information based on at least a portion of the retrieved predetermined number of prior analyte level signals.

The trend information may be determined based on analyte sensor sensitivity.

Updating the prior trend information may be based on the analyte sensor sensitivity.

Updating the prior trend information may include determining an updated analyte level of the at least a portion of the retrieved predetermined number of stored analyte levels based on the analyte sensor sensitivity.

One aspect may include a display unit operatively coupled to the data processing unit to display one or more of the trend information, prior trend information or the updated prior trend information.

The data processing unit may be configured to modify the display of the trend information based on the updated prior trend information.

Each of the predetermined number of stored analyte level signals and the analyte level signal may be temporally separated by a predetermined time period.

The predetermined time period may include a data transmission rate of the communication unit.

The communication unit may be configured for wireless communication.

In one embodiment, a method of determining glucose trend information may comprise receiving a signal related to a monitored analyte level from an in vivo analyte sensor, retrieving at least one stored signal related to the monitored analyte level received from the analyte sensor, determining a calibration scaling factor, applying the determined calibration scaling factor to the received signal and to the retrieved at least one stored signal to generate scaled data, and determining glucose trend information based on the generated scaled data.

One aspect may include when the calibration scaling factor is applied to the retrieved at least one stored signal, the retrieved at least one stored signal is modified.

One aspect may include storing the generated scaled data.

Determining the calibration scaling factor may include receiving a blood glucose measurement value.

One aspect may include determining a sensitivity based on the received blood glucose measurement value and the received signal related to the monitored analyte level.

The sensitivity may be related to the calibration scaling factor.

Various other modifications and alterations in the structure and method of operation of this invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

What is claimed is:

1. A method of determining glucose information, comprising:

receiving a signal associated with a monitored glucose level from an in vivo glucose sensor;  
retrieving stored signals associated with the monitored glucose level;  
determining a number of corrupt signals of the retrieved stored signals and a number of non-corrupt signals of the retrieved stored signals;



35

- determining that the retrieved stored signals do not exceed a preset tolerance level such that the number of corrupt signals is not more than a predetermined number;
- determining a rate of change of the monitored glucose level based on the received signal associated with the monitored glucose level and the non-corrupt signals of the retrieved stored signals; and
- delivering medicament using a medical device based on the determined rate of change.
2. The method of claim 1, wherein the rate of change is determined based on glucose sensor sensitivity.
3. The method of claim 1, including displaying the determined rate of change.
4. The method of claim 1, including modifying a display of the determined rate of change.
5. The method of claim 4, wherein modifying the display of the determined rate of change includes modifying a display of a trend arrow indicator.
6. The method of claim 5, wherein modifying the display of the trend arrow indicator includes displaying a change in the trend arrow indicator position.
7. The method of claim 6, wherein the trend arrow indicator position includes one of five or less displayed positions.
8. The method of claim 1, wherein the retrieved stored signals and the received signal associated with the monitored glucose level are temporally separated.
9. An apparatus, comprising:
- a data storage unit; and
  - a data processing unit operatively coupled to the data storage unit including programming to receive a signal associated with a monitored glucose level from an in vivo glucose sensor, retrieve from the data storage unit

36

- stored signals associated with the monitored glucose level, determine a number of corrupt signals of the retrieved stored signals and a number of non-corrupt signals of the retrieved stored signals, determine that the retrieved stored signals do not exceed a preset tolerance level such that the number of corrupt signals is not more than a predetermined number, determine a rate of change of the monitored glucose level based on the received signal associated with the monitored glucose level and the non-corrupt signals of the retrieved stored signals, and deliver medicament using a medical device based on the determined rate of change.
10. The apparatus of claim 9, further including a display operatively coupled to the data processing unit to display the determined rate of change.
11. The apparatus of claim 10, wherein the data processing unit includes programming to modify the display of the determined rate of change.
12. The apparatus of claim 11, wherein the data processing unit includes programming to modify the display of a trend arrow indicator based on the determined rate of change.
13. The apparatus of claim 12, wherein the data processing unit includes programming to modify the display of the trend arrow indicator by displaying a change in the trend arrow indicator position.
14. The apparatus of claim 13, wherein the trend arrow indicator position includes one of five or less displayed positions.
15. The apparatus of claim 9, wherein the retrieved stored signals and the received signal associated with the monitored glucose level are temporally separated.

\* \* \* \* \*